<SEC-DOCUMENT>0001654954-25-007766.txt : 20250703
<SEC-HEADER>0001654954-25-007766.hdr.sgml : 20250703
<ACCEPTANCE-DATETIME>20250703160910
ACCESSION NUMBER:		0001654954-25-007766
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20250703
DATE AS OF CHANGE:		20250703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288515
		FILM NUMBER:		251105628

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>cvm_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<html><head><title>cvm_s3.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM S-3</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registration Statement Under</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES ACT OF 1933</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">CEL-SCI CORPORATION</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in charter)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:100%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Colorado</strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;<strong>84-09l6344 </strong></p></td> <td style="width:10%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd. #802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22182</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(703) 506-9460</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer I.D. Number)</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address, including zip code, and telephone number including area of principal executive offices)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:100%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Geert Kersten</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd. #802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22182</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>(703) 506-9460</u></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Name and address, including zip code, and telephone number,&nbsp;including area code, of agent for service)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Copies of all communications, including all communications sent</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">to the agent for service, should be sent to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">William T. Hart, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Hart &amp; Hart</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1624 Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Denver, Colorado 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(303) 839-0061</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">From time to time after this Registration Statement</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">becomes effective as determined by market conditions</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&#9746;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&nbsp;&nbsp;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large&nbsp;accelerated&nbsp;filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Non-accelerated filer</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9746;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant hereby amends this Registration&nbsp;statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall&nbsp;thereafter&nbsp;become effective in accordance with Section 8(a) of the&nbsp;Securities&nbsp;Act of l933 or until the&nbsp;Registration&nbsp;Statement&nbsp;shall become effective on such date as the Commission,&nbsp;acting pursuant to said Section 8(a), may determine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp; </strong></p> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PROSPECTUS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI Corporation may offer from time to time shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these<strong>&nbsp;</strong>securities issuable upon conversion of preferred stock or upon the exercise of warrants<strong>,</strong>&nbsp;at an initial offering price not to exceed $100,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Specific terms pertaining to the securities offered by this prospectus will be set forth in one or more accompanying prospectus supplements, together with the terms of the offering and the initial price and the net proceeds to CEL-SCI from the sale.&nbsp;&nbsp;The prospectus supplement will set forth, without limitation, the terms of the offering and sale of such securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may sell the securities offered by this prospectus directly, through agents designated from time to time, or through underwriters or dealers. If any agents of CEL-SCI or any underwriters or dealers are involved in the sale of the securities, the names of the agents, underwriters or dealers, any applicable commissions and discounts, and the net proceeds to CEL-SCI will be set forth in the applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may not use this prospectus to complete sales of its securities unless this prospectus is accompanied by a prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Effective May 20, 2025, CEL-SCI completed a 1-for-30 reverse stock split of its outstanding common stock (&#8220;Reverse Stock Split&#8221;). The reverse stock split did not reduce the number of authorized shares of our common stock or preferred stock. All share and per share amounts in this prospectus supplement have been adjusted to give effect to the reverse stock split. However, any documents incorporated by reference, including the financial statements, do not reflect the Reverse Stock Split</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>The securities offered by this prospectus are speculative and involve a high degree of risk and should be purchased only by persons who can afford to lose their entire investment.&nbsp;&nbsp;For a description of certain important factors that should be considered by prospective investors, see "Risk Factors" beginning on page 10 of this prospectus.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or has passed upon the accuracy or adequacy of this prospectus.&nbsp;&nbsp;Any representation to the contrary is a criminal offense.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's common stock is traded on the NYSE American under the symbol &#8220;CVM&#8221;.&nbsp;&nbsp;On June 30, 2025 the closing price of CEL-SCI&#8217;s common stock on the NYSE American was $2.29.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The date of this Prospectus is ________, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="prospe">PROSPECTUS SUMMARY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>THIS SUMMARY IS QUALIFIED BY THE OTHER INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>THE OFFERING</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities Offered:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may offer from time to time shares of common stock, preferred stock,<strong>&nbsp;</strong>convertible preferred stock, rights, warrants, units consisting of one or more of the foregoing securities, as well as any of these securities issuable upon the conversion of preferred stock or upon the exercise of the warrants, at an initial offering price not to exceed $100,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale.&nbsp;&nbsp;CEL-SCI may not use this prospectus to complete sales of its securities unless this prospectus is accompanied by a prospectus supplement.&nbsp;&nbsp;See the &#8220;Plan of Distribution&#8221; section of this prospectus for additional information concerning the manner in which CEL-SCI&#8217;s securities may be offered.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock Outstanding:</p></td> <td style="width:2%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of June 30, 2025, CEL-SCI had&nbsp;5,321,341 outstanding shares of common stock.&nbsp;&nbsp;The number of outstanding shares does not give effect to shares which may be issued upon the exercise and/or conversion of options or warrants.&nbsp;&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk Factors:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The purchase of the securities offered by this prospectus involves a high degree of risk.&nbsp;&nbsp;Risk factors include the lack of revenues and history of loss, need for additional capital and need for FDA approval.&nbsp;&nbsp;See the &#8220;Risk Factors" section of this prospectus for additional Risk Factors.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock NYSE American symbol:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">CVM</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>BUSINESS OVERVIEW</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>OVERVIEW AND PRODUCT CANDIDATES</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this prospectus as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS AND PATH FORWARD</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Immunotherapy is a large, high growth market.</u></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Source</u>:&nbsp; <u>https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</u> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine<sup style="vertical-align:super">&#174;</sup> (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><u>given first</u></em><u>, right after diagnosis, before any other treatment including surgery. </u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&nbsp; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&nbsp; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>What is Multikine and who is it for?</u></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><u>before</u></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">No lymph node involvement (via PET imaging)</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Low PD-L1 tumor expression (TPS&lt;10) (via biopsy)</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50).&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Keytruda was approved by FDA in June 2025 as a prospective (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-LI at the positive level. In Merck's Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30% compared with standard of care, in patients whose tumors expressed PD-L1 (CPS&gt;1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit&nbsp;from&nbsp;Keytruda.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In contrast to the results of the KEYNOTE-689. CEL-SCI's Phase 3 study showed that Multikine treated patients whose tumors expressed low (Tumor Portion Score [TPS&lt;10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI's Phase 3 study had low to zero levels&nbsp;of&nbsp;PD-L1.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>CEL-SCI believes Multikine leads to longer survival with no safety issues.</u></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong><em><u>risk of death cut in half at five years</u></em></strong><strong><em> </em></strong>versus the control;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference on Head and Neck Oncology (ECHNO), the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and the 2023 American Head and Neck Society (AHNS). These publications can be accessed at <u>http://www.cel-sci.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Multikine</u></strong><strong><u> works by inducing pre-surgical responses.</u></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine causes pre-surgical responses;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-surgical responses lead to longer life;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><u>none</u><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img15.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&nbsp; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup.&nbsp; The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img16.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Multikine cut the 5-year risk of death in half in the target population.</u></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img17.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img18.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s physician consultants have informed CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval - for the hazard ratio - in this case) is still below (better) than the hazard ratio required for most drug approvals. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&nbsp; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&nbsp; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img19.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img20.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.&nbsp; CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful?</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3img21.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has been shown to be safe. Every situation is different and depends on the specific facts.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IN CONCLUSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data</strong>: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit (95% Confidence Interval) of 0.66.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need</strong>: Multikine focuses on the 70% of patients (based on our 928 patient Phase 3 study) not well served by Keytruda.&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population</strong>: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FDA pathway</strong>: CEL-SCI&#8217;s goal is to begin the 212-patient confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later with the potential to seek early approval after full enrollment.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>FORWARD LOOKING STATEMENTS</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This prospectus and the documents that are incorporated or deemed to be incorporated by reference into this prospectus, contain or incorporate by reference &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceeding;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the success of our clinical studies for our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding federal, state and foreign regulatory requirements;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the therapeutic benefits and effectiveness of our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the safety profile and related adverse events of our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations as to future financial performance, expense levels and liquidity sources;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">anticipated trends and challenges in our potential markets;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to attract, retain and motivate key personnel;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to continue as a going concern; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our liquidity.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement, the risk factors set forth under the heading &#8220;Risk Factors&#8221; and information elsewhere in this prospectus and in the documents incorporated or deemed to be incorporated by reference into this prospectus. The forward-looking statements contained in this prospectus and any document incorporated or deemed to be incorporated by reference in this prospectus, speak only as of their respective dates.&nbsp;&nbsp;Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this prospectus or to<strong>&nbsp;</strong>reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this prospectus and the documents that are incorporated by reference into this prospectus may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.<strong> </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="risk">RISK FACTORS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Investment in our common stock offered pursuant to this prospectus and any prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and any such reports we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Securities Exchange Act of 1934, and the risk factors and other information contained in any prospectus supplement and any applicable free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="SELECTEDFINANCIAL">SELECTED FINANCIAL DATA REFLECTING REVERSE STOCK SPLIT</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Reverse Stock Split</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On May 20, 2025, we effected a 1-for-30 reverse stock split of our common stock. Based on such reverse stock split, the total number of outstanding shares of common stock was adjusted from 94,037,256 to approximately 3,135,021. The par value per common share remained unchanged at $0.01. The audited consolidated financial statements of CEL-SCI Corporation included in the Annual Report on Form 10-K for the year ended September 30, 2024, and the unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the quarterly periods ended December 31, 2024 and March 31, 2025, which are incorporated by reference into this prospectus are presented without giving effect to the reverse stock split. Except where the context otherwise requires, share numbers in this prospectus supplement reflect the 1-for-30 reverse stock split of our common stock.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following selected financial data has been derived from our audited consolidated financial statements included in our Annual Report on Form 10-K filed with the SEC on January 13, 2025, and our unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q filed with the SEC on February 14, 2025 and May 14, 2025, as adjusted to reflect the reverse stock split for all periods presented. Our historical results are not indicative of the results that may be expected in the future and results of interim periods are not indicative of the results for the entire year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AS REPORTED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30.</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27,579,921 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32,365,855 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.51 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.73 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,044,989</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,479,865</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at year end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,787,104</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,422,304</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: 1px solid;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,073,062 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,709,524 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.11 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.14 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,325,855</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,470,600</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at period end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74,084,041</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,787,104</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,645,451 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,954,415 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,572,389 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,244,891 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.18 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.28 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.08 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.14 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74,827,450</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,228,860</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84,540,132</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,006,442</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at period end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84,349,756</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,787,104</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84,349,756</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,787,104</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AS ADJUSTED FOR 1-FOR-30 REVERSE STOCK SPLIT (unaudited)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30.</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(27,579,921 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32,365,855 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15.31 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(21.83 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,801,500</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,482,662</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at year end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,126,237</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,580,743</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,073,062 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,709,524 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3.25 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.15 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,177,529</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,615,687</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at period end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,469,468</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,126,237</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,645,451 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,954,415 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,572,389 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,244,891 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5.47 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8.33 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.33 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.18 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,494,248</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,674,295</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,818,004</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,733,548</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common shares outstanding at period end</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,811,659</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,126,237</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,811,659</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,126,237</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="use">USE OF PROCEEDS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We intend to use the net proceeds from the sale of the securities as set forth in any applicable prospectus supplement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="market">MARKET FOR CEL-SCI&#8217;S COMMON STOCK</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our common stock is publicly traded on the NYSE American under the symbol &#8220;CVM&#8221;. The following table sets forth, for the periods indicated, the high and low intraday sale prices of our common stock as reported by the NYSE American. These prices have been adjusted to reflect a reverse stock split which was effective May 20, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Quarter Ending</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>High</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Low</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FY 2023</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2022</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64.50</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88.20</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55.80</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89.70</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FY 2024</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.20</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71.70</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33.00</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FY 2025</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.10</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">03/31/2025</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.41</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.65</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">06/30/25</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.98</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of June 30, 2025, there were&nbsp;5,321,341 outstanding<strong>&nbsp;</strong>shares of our common stock outstanding held by approximately 435 holders of record.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive dividends as may be declared by the Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI&#8217;s assets after payment of liabilities. The Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The provisions in CEL-SCI&#8217;s Articles of Incorporation relating to CEL-SCI&#8217;s preferred stock would allow CEL-SCI&#8217;s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI&#8217;s common stock.&nbsp;&nbsp;The issuance of preferred stock with such rights may make the removal of management more difficult, even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The market price of CEL-SCI&#8217;s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI&#8217;s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI&#8217;s common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="dilut">DILUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of March 31, 2025, we had a net tangible book value of $2.79 per share. An investor purchasing shares pursuant to any prospectus supplement we subsequently file will suffer dilution equal in amount to the difference between the price paid for the securities we offer and our net tangible book value at the time of purchase.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="plan">PLAN OF DISTRIBUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may sell shares of its common stock, preferred stock, convertible preferred stock, rights, warrants, or units consisting of any of the foregoing, as well as any securities issuable upon the conversion of preferred stock or upon the exercise of warrants in and/or outside the United States:&nbsp;(i) through underwriters, placement agents, or dealers; (ii) directly to a limited number of purchasers or to a single purchaser; or (iii) through agents.&nbsp;&nbsp;The applicable prospectus supplement with respect to the offered securities will set forth the name or names of any underwriters or agents, if any, the purchase price of the offered securities and the proceeds to CEL-SCI from such sale, any delayed delivery arrangements, any underwriting discounts, commissions, and other items constituting underwriters' or placement agents&#8217; compensation, the public offering price and any discounts or concessions allowed or reallowed or paid to dealers and any compensation paid to an underwriter or a placement agent.&nbsp;&nbsp;The public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Notwithstanding the above, the maximum commission or discount to be received by any NASD member or independent broker-dealer will not be greater than 10% in connection with the sale of any securities offered by means of this prospectus or any related prospectus supplement, exclusive of any non-accountable expense allowance.&nbsp;&nbsp;Any securities issued by CEL-SCI to any FINRA member or independent broker-dealer in connection with an offering of CEL-SCI&#8217;s securities will be considered underwriting compensation and may be restricted from sale, transfer, assignment, or hypothecation for a number of months following the effective date of the offering, except to officers or partners (not directors) of any underwriter or member of a selling group and/or their officers or partners.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s securities may be sold:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At a fixed price.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As the result of the exercise of warrants or rights, or the conversion of preferred shares, at fixed or varying prices, as determined by the terms of the warrants, rights or convertible securities.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At varying prices in "at the market" offerings.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In privately negotiated transactions, at fixed prices which may be changed, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale.&nbsp;&nbsp;The securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.&nbsp;&nbsp;The underwriter or underwriters with respect to a particular underwritten offering of securities will be named in the prospectus supplement relating to such offering and, if an underwriting syndicate is used, the managing underwriter or underwriters will be set forth on the cover of such prospectus supplement.&nbsp;&nbsp;Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters may be obligated to purchase all the offered securities if any are purchased.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If dealers are used in the sale of offered securities in respect of which the prospectus<strong>&nbsp;</strong>supplement is delivered, CEL-SCI will sell the offered securities to the dealers as principals.&nbsp;&nbsp;The dealers may then resell the offered securities to the public at varying prices to be determined by the dealers at the time of resale.&nbsp;&nbsp;The names of the dealers and the terms of the transaction will be set forth in the prospectus supplement relating to the securities sold to the dealers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If an agent is used in an offering, the agent will be named, and the terms of the agency will be set forth, in the prospectus supplement.&nbsp;&nbsp;Unless otherwise indicated in the prospectus supplement, an agent will act on a best efforts basis for the period of its appointment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The securities may be sold directly by CEL-SCI to institutional investors or others, who may be deemed to be underwriters within the meaning of the Securities Act of 1933 with respect to any resale of the securities purchased by the institutional investors.&nbsp;&nbsp;The terms of any of the sales, including the terms of any bidding or auction process, will be described in the applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may permit agents or underwriters to solicit offers to purchase its securities at the public offering price set forth in a prospectus supplement pursuant to a delayed delivery arrangement providing for payment and delivery on the date stated in the prospectus supplement.&nbsp;&nbsp;Any delayed delivery contract will contain definite fixed price and quantity terms.&nbsp;&nbsp;The obligations of any purchaser pursuant to a delayed delivery contract will not be subject to any market outs or other conditions other than the condition that the delayed delivery contract will not violate applicable law.&nbsp;&nbsp;In the event the securities underlying the delayed delivery contract are sold to underwriters at the time of performance of the delayed delivery contract, those securities will be sold to those underwriters.&nbsp;&nbsp;Each delayed delivery contract shall be subject to CEL-SCI&#8217;s approval.&nbsp;&nbsp;CEL-SCI will pay the commission indicated in the prospectus supplement to underwriters, dealers or agents soliciting purchases of securities pursuant to delayed delivery arrangements accepted by CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Notwithstanding the above, while prospectus supplements may provide specific offering terms, or add to or update information contained in this prospectus, any fundamental changes to the offering terms will be made by means of a post-effective amendment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Agents, dealers and underwriters may be entitled under agreements entered into with CEL-SCI to indemnification from CEL-SCI against certain civil liabilities, including liabilities under the Securities Act, or to contributions with respect to payments made by such agents, dealers or underwriters.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="descrip">DESCRIPTION OF SECURITIES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Common Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is authorized to issue 600,000,000 shares of common stock, (the "common stock").&nbsp;&nbsp;Holders of common stock are each entitled to cast one vote for each share held of record on all matters presented to shareholders.&nbsp;&nbsp;Cumulative voting is not allowed; hence, the holders of a majority of the outstanding shares of our common stock can elect all directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefor and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI's assets after payment of liabilities.&nbsp;&nbsp;The board is not obligated to declare a dividend.&nbsp;&nbsp;It is not anticipated that dividends will be paid in the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock do not have preemptive rights to subscribe to additional shares if issued by CEL-SCI.&nbsp;&nbsp;There is no conversion, redemption, sinking fund or similar provision regarding the common stock.&nbsp;&nbsp;All of the outstanding shares of common stock are fully paid and non-assessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Preferred Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is authorized to issue up to 200,000 shares of preferred stock.&nbsp;&nbsp;CEL-SCI's Articles of Incorporation provide that the Board of Directors has the authority to divide the preferred stock into series and, within the limitations provided by Colorado statute, to fix by resolution the voting power, designations, preferences, and relative participation, special rights, and the qualifications, limitations or restrictions of the shares of any series so established.&nbsp;&nbsp;As the Board of Directors has authority to establish the terms of, and to issue, the preferred stock without shareholder approval, the preferred stock could be issued to defend against any attempted takeover of CEL-SCI.&nbsp;&nbsp;As of June 30, 2025, no shares of preferred stock were outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Rights Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In October 2020, we declared a dividend of one Series A Right and one Series B Right, or collectively the Rights, for each share of our common stock which was outstanding on October 30, 2020.&nbsp; When the Rights become exercisable, each Series A Right will entitle the registered holder, subject to the terms of a Rights Agreement, to purchase from us one share of our common stock at a price equal to 20% of the market price of our common stock on the exercise date, although the price may be adjusted pursuant to the terms of the Rights Agreement.&nbsp; If after a person or group of affiliated persons has acquired 15% or more of our common stock or following the commencement of a tender offer for 15% or more of our outstanding common stock (i) we are acquired in a merger or other business combination and we are not the surviving corporation, (ii) any person consolidates or merges with us and all or part of our common shares are converted or exchanged for securities, cash or property of any other person, or (iii) 50% or more of our consolidated assets or earning power are sold, proper provision will be made so that each holder of a Series B Right will thereafter have the right to receive, upon payment of the exercise price of $100 (subject to adjustment), that number of shares of common stock of the acquiring company which at the time of such transaction has a market value that is twice the exercise price of the Series B Right.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The description and terms of the Rights are set forth in a Rights Agreement between the Company and Computershare Trust Company, N.A., as Rights Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Distribution of Rights</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Initially, stockholders will not receive separate certificates for the Rights as the Rights will be represented by outstanding common stock certificates. Until the exercise date, the Rights cannot be bought, sold or otherwise traded separately from the common stock. Certificates for common stock carry a notation that indicates that Rights are attached to the common stock and incorporate the terms of the Rights Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Separate certificates representing the Rights will be distributed as soon as practicable after the earliest to occur of:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days following a public announcement that a person or group of affiliated or associated persons has acquired beneficial ownership of 15% or more of our outstanding common stock, or</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days (or such later date as may be determined by action of our board of directors prior to such time as any person or group of affiliated persons has acquired 15% or more of our common stock) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of our outstanding common stock.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The earlier of such dates described above is called the &#8220;distribution date.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Until the distribution date (or earlier redemption or expiration of the Rights), the surrender or transfer of any certificates for common stock outstanding as of the record date, even without such notation, will also constitute the transfer of the Rights associated with the common stock represented by such certificate. As soon as practicable following the distribution date, separate certificates evidencing the Rights will be mailed to holders of record of the common stock as of the close of business on the distribution date and such separate right certificates alone will evidence the Rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Exercise and Expiration</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The holders of the Rights are not required to take any action until the Rights become exercisable. The Rights are not exercisable until the distribution date.&nbsp; Holders of the Rights will be notified by us that the Rights have become exercisable.&nbsp; The Rights will expire on October 30, 2025, unless the expiration date is extended or unless the Rights are earlier redeemed by us as described below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Redemption</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At any time prior to the distribution date, our board of directors may redeem the Rights in whole, but not in part, at a price of $0.0001 per Right. Subject to the foregoing, the redemption of the Rights may be made effective at such time, on such basis and with such conditions as our board of directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only entitlement of the holders of Rights will be to receive the redemption price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Exchange Option</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At any time after a person or group of affiliated persons has acquired 15% or more of our common stock or following the commencement of a tender offer for 15% or more of our outstanding common stock, and prior to the acquisition by such person of 50% or more of the outstanding common stock, our board of directors may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Other Provisions</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The terms of the Rights may be amended by our board of directors without the consent of the holders of the Rights, except that from and after such time a person or group of affiliated persons has acquired 15% or more of our common stock no such amendment may adversely affect the interests of the holders of the Rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Until a Right is exercised, the holder of the Right, as such, will not have any rights as a stockholder, including, without limitation, the right to vote or to receive dividends.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Rights may have certain anti-takeover effects. The Rights will cause substantial dilution to a person or group that attempts to acquire us on terms not approved by our board of directors. However, the Rights should not interfere with any merger or other business combination approved by a majority of our board of directors because the Rights may be redeemed by us at any time prior to the distribution date. Thus, the Rights are intended to encourage persons who may seek to acquire control of us to initiate such an acquisition through negotiations with our board of directors. However, the effect of the Rights may be to discourage a third party from making a partial tender offer or otherwise attempting to obtain a substantial position in the equity securities of, or seeking to obtain control of, us.&nbsp; To the extent any potential acquisition is deterred by the Rights, the Rights may have the effect of preserving incumbent management in office.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><em>Attorneys&#8217; Fees in Stockholder Actions </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our bylaws include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event that any stockholder initiates or asserts a claim against us, or any of our officers or directors, including any derivative claim or claim purportedly filed on our behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse us and any of our officers or directors named in the action, for all fees, costs and expenses of every kind and description, including but not limited to all reasonable attorneys&#8217; fees and other litigation expenses, that we or our officers or directors who were named in the action may incur in connection with such claim. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our fee-shifting provision is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. There are several types of remedies that a stockholder may seek in connection with an action or proceeding against us, including declaratory or injunctive relief, or monetary damages. If a stockholder is not successful in obtaining a judgment that substantially achieves in substance, such as in the case of a claim for declaratory or injunctive relief, or amount, such as in the case of a claim for monetary damages, our and our officers&#8217; and directors&#8217; litigation expenses may be shifted to the stockholder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Fee-shifting provisions are relatively new and untested. The case law and potential legislative action on fee shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether our ability to invoke our fee-shifting bylaw in connection with claims under the federal securities laws, including claims related to this offering, would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of our fee shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. We cannot assure you that we will or will not invoke our fee-shifting bylaw in any particular dispute, including any claims related to this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a stockholder that brings any such claim is unable to obtain the required judgment, the attorneys&#8217; fees and other litigation expenses that might be shifted to such a stockholder are potentially significant. This fee-shifting bylaw, therefore, may dissuade or discourage stockholders (and their attorneys) from initiating lawsuits or claims against us or our directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent our stockholders or otherwise discourage plaintiffs&#8217; attorneys from representing our stockholders at all. As a result, this bylaw may limit the ability of stockholders to affect the management and direction of our company, particularly through litigation or the threat of litigation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Transfer Agent</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Computershare, Inc., of Denver, Colorado, is the transfer agent for CEL-SCI's common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="legal">LEGAL MATTERS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The validity of the securities being offered by this prospectus will be passed upon for us by Hart &amp; Hart, Denver, Colorado.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="expert">EXPERTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The financial statements of CEL-SCI Corporation (the Company) as of September 30, 2024 and 2023 and for each of the two years in the period ended September 30, 2024 incorporated by reference in this Registration Statement have been so incorporated in reliance on the reports of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="inde">INDEMNIFICATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's bylaws authorize indemnification of a director, officer, employee or agent of CEL-SCI against expenses incurred by such person in connection with any action, suit, or proceeding to which such person is named a party by reason of such person having acted or served in such capacity, except for liabilities arising from such person's own misconduct or negligence in performance of such person's duty.&nbsp;&nbsp;In addition, even a director, officer, employee, or agent of CEL-SCI who was found liable for misconduct or negligence in the performance of his duty may obtain such indemnification if, in view of all the circumstances in the case, a court of competent jurisdiction determines such person is fairly and reasonably entitled to indemnification.&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, or persons controlling CEL-SCI pursuant to the foregoing provisions, CEL-SCI has been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is therefore unenforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="addit">ADDITIONAL INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is subject to the requirements of the Securities Exchange Act of l934 and is required to file 10-K, 10-Q, 8-K reports, proxy statements and other information with the Securities and Exchange Commission.&nbsp;&nbsp; The Commission maintains an Internet site that contains reports, proxy and information statements, and other information regarding CEL-SCI.&nbsp;&nbsp;The address of that site is http://www.sec.gov.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has filed with the Securities and Exchange Commission a Registration Statement under the Securities Act of l933, as amended, with respect to the securities offered by this prospectus.&nbsp;&nbsp;This prospectus does not contain all of the information set forth in the Registration Statement.&nbsp;&nbsp;For further information with respect to CEL-SCI and such securities, reference is made to the Registration Statement and to the exhibits filed with the Registration Statement.&nbsp;&nbsp;Statements contained in this prospectus as to the contents of any contract or other documents are summaries which are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified in all respects by such reference.&nbsp;&nbsp;The Registration Statement and related exhibits may also be examined at the Commission&#8217;s internet site. &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will provide, without charge, to each person to whom a copy of this prospectus is delivered, including any beneficial owner, upon the written or oral request of such person, a copy of any or all of the documents incorporated by reference below (other than exhibits to these documents, unless the exhibits are specifically incorporated by reference into this prospectus). Requests should be directed to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8229 Boone Blvd., #802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Vienna, Virginia&nbsp;&nbsp;22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(703) 506-9460</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">INCORPORATION OF DOCUMENTS BY REFERENCE &#8211; We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this Registration Statement, and any future filings we will make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our Annual Report on Form 10-K for the fiscal year ended September 30, 2024;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our Quarterly Reports on Form 10-Q for the periods ended December 31, 2024 and March 31, 2025;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our Current Reports on Form 8-K filed with the SEC on November 13, 2024, November 15, 2024, December 31, 2024, March 18, 2025, May 19, 2025 and May 23, 2025;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our Proxy Statement relating to our May 19, 2025 Annual Meeting of Shareholders; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 1996 and all amendments and reports updating that description</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All documents filed with the Commission by CEL-SCI pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this prospectus and prior to the termination of this offering shall be deemed to be incorporated by reference into this prospectus and to be a part of this prospectus from the date of the filing of such documents.&nbsp;&nbsp;Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus or in any subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.&nbsp;&nbsp;Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The documents incorporated by reference may be accessed at the website of the Securities and Exchange Commission: <u>www.sec.gov</u> and at CEL-SCI's website:&nbsp;<u>www.cel-sci.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Investors are entitled to rely upon information in this prospectus or incorporated by reference at the time it is used by CEL-SCI to offer and sell securities, even though that information may be superseded or modified by information subsequently incorporated by reference into this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="TOC">TABLE OF CONTENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#prospe">Prospectus Summary</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#risk">Risk Factors</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">13</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SELECTEDFINANCIAL">Selected Financial Data Reflecting Reverse Stock Split</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">13</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#use">Use of Proceeds</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">14</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#market">Market for CEL-SCI&#8217;s Common Stock</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">14</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#dilut">Dilution</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#plan">Plan of Distribution</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#descrip">Description of Securities</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">17</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#legal">Legal Matters</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#expert">Experts</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#inde">Indemnification</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#addit">Additional Information</a></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PROSPECTUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">No dealer salesman or other person has been authorized to give any information or to make any representations, other than those contained in this prospectus.&nbsp;&nbsp;Any information or representation not contained in this prospectus must not be relied upon as having been authorized by CEL-SCI.&nbsp;&nbsp;This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, the securities offered hereby in any state or other jurisdiction to any person to whom it is unlawful to make such offer or solicitation.&nbsp;&nbsp;Neither the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create an implication that there has been no change in the affairs of CEL-SCI since the date of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART II</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Information Not Required in Prospectus</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 14.&nbsp;&nbsp;<u>Other Expenses of Issuance and Distribution</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">SEC Filing Fee</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,310</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Legal Fees and Expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Accounting Fees and Expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Miscellaneous Expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">535</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:left;">TOTAL</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">60,845</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All expenses other than the SEC filing fees are estimated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 15. <u>Indemnification of Officers and Directors</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Section 7-109-102 of the Colorado Revised Statutes and CEL-SCI's Bylaws<strong>,</strong>&nbsp;CEL-SCI may indemnify any and all of its officers, directors, employees or agents or former officers, directors, employees or agents, against expenses actually and necessarily incurred by them, in connection with the defense of any legal proceeding or threatened legal proceeding, except as to matters in which such persons shall be determined to not have acted in good faith and in the best interest of CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 16.&nbsp;&nbsp;<u>Exhibits </u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:6%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(a)</p></td> <td colspan="2" style="width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Articles of Incorporation</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(b)</p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(c)</p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles (Name change only)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(c) of CEL-SCI's Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420002630/cvm_ex3d.htm">3(d)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420002630/cvm_ex3d.htm">Bylaws (as amended)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex3f.htm">3(f)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex3f.htm">Amended Articles (reverse stock split only)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">________________________</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">4</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Shareholders Rights Agreement, as Amended</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4&nbsp;filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">4(b)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">Incentive Stock Option Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on October 7, 2016 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-214031).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">4(c)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">Non-Qualified Stock Option Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on August 30, 2024 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-281884).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">4(d)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">Stock Bonus Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (c) filed on December 22, 2023 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-276238).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">4(e)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">Stock Compensation Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (e) filed on January 24, 2020 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-236063).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">4(f)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">2014 Incentive Stock Bonus Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;Filed with Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">10(l)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">First Amendment to Development Supply&nbsp;and Distribution Agreement with Orient&nbsp;Europharma.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(m)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">10(m)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">Exclusive License and Distribution&nbsp;Agreement with Teva&nbsp;Pharmaceutical Industries&nbsp;Ltd.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(n)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">10(n)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">Lease Agreement</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(o)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(p)</p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Licensing Agreement with Byron Biopharma</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(i) of CEL-SCI&#8217;s report on Form 8-K dated March 27, 2009</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">10(z)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">Development, Supply and Distribution Agreement with Orient Europharma</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(z) filed with CEL-SCI&#8217;s report on Form 10-K for the year ended September 30, 2003.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">10 (rr)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">Assignment and Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and GCP Clinical Studies, Ltd.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(rr) of CEL-SCI&#8217;s report on Form 10-K/A report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">10 (ss)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">Service Agreement with GCP Clinical Studies, Ltd., together with Amendment 1 thereto*</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ss) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">10 (tt)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">Joinder Agreement with PLIVA Hrvatska d.o.o.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(tt) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">10 (uu)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Master Service Agreement with Ergomed Clinical Research, Ltd., and Clinical Trial Orders thereunder</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(uu) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">10 (vv)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research Ltd., dated April 19, 2013, as amended</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(vv) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">10 (ww)</a></p></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Co-Development and Revenue Sharing Agreement II:&nbsp;&nbsp;Cervical Intraepithelial </a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical Research Ltd., dated October 10, 2013, as amended</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ww) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td colspan="2" style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:6%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">10 (xx)</a></p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">Co-Development and Revenue Sharing Agreement III: Anal warts and anal intraepithelial neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical Research Ltd., dated October 24, 2013</a></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 10(xx) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">10 (yy)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">Master Services Agreement with Aptiv Solutions, Inc.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(yy) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">10 (zz)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">Project Agreement Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and 2 thereto*</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(zz) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">10 (aaa)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">Second Amendment to Development Supply and Distribution Agreement with Orient Europharma</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(aaa) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10 (iii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated&nbsp; September 15, 2015</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10 (iii)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">10 (mmm)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">Employment Agreement with Geert Kersten (2019-2023)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.7) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">10 (nnn)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">Employment Agreement with Patricia Prichep (2019-2022)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.8) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">10 (ooo)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">Employment Agreement with Eyal Taylor (2019-2022)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.9) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">10 (ppp)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">Extension of Employment Agreement with Patricia Prichep (2023-2027)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.10) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">10 (qqq)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">Extension of Employment Agreement with Eyal Talor (2023-2027)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.11) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">10 (rrr)</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">Extension of Employment Agreement with Geert Kersten (2023-2027)</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10.10 of CEL-SCI&#8217;s report on Form 8-K dated October 26, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">97</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">Policy relating to Recovery of Erroneously Awarded Compensation</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 97 of CEL-SCI&#8217;s 10-K report for the year ended September 30, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">23.1</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex231.htm">Consent of Hart &amp; Hart, LLC</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex232.htm">23.2</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex232.htm">Consent of BDO USA, P.C.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex107.htm">107</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex107.htm">Filing Fee Table</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 17. <u>Undertakings</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The undersigned registrant hereby undertakes:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(i)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To include any prospectus required by Section l0(a)(3) of the Securities Act;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(ii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(iii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement, including (but not limited to) any addition or deletion of a managing underwriter.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">That, for the purpose of determining any liability under the Securities Act of l933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Insofar as indemnification for liabilities arising under the Securities Act of l933 (the &#8220;Act&#8221;) may be permitted to directors, officers and controlling persons of the Registrant, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.&nbsp;&nbsp;In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>POWER OF ATTORNEY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The registrant and each person whose signature appears below hereby authorizes the agent for service named in this registration statement, with full power to act alone, to file one or more amendments (including post-effective amendments) to this registration statement, which amendments may make such changes in this registration statement as such agent for service deems appropriate, and the Registrant and each such person hereby appoints such agent for service as attorney-in-fact, with full power to act alone, to execute in the name and in behalf of the Registrant and any such person, individually and in each capacity stated below, any such amendments to this registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vienna, State of Virginia, on the&nbsp;3<sup style="vertical-align:super">rd</sup>&nbsp;day of July 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2" style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CEL-SCI CORPORATION</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp;&nbsp;</p></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten, Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Patricia Prichep</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep, Chief Financial and Operations Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Signature</strong></p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Title</strong></p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Date</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">/s/ Geert Kersten</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer and Director</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">July 3, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Bruno Baillavoine</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chairman of the Board, Director</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">July 3, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Robert Watson</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">July 3, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>REGISTRATION STATEMENT ON FORM S-</strong><strong>3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.F
<SEQUENCE>2
<FILENAME>cvm_ex3f.htm
<DESCRIPTION>ATTACHMENT TO ARTICLES OF AMENDMENT
<TEXT>
<html><head><title>cvm_ex3f.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 3(f)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ATTACHMENT TO ARTICLES OF AMENDMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is added to Article 4:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Effective May 19, 2025, all outstanding shares of the Company&#8217;s common stock were combined on a 30-for-1 basis. Each outstanding share of the Company&#8217;s common stock will be combined into one share of common stock.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>3
<FILENAME>cvm_ex5.htm
<DESCRIPTION>EX-5
<TEXT>
<html><head><title>cvm_ex5.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 5</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:18pt"><em>HART &amp; HART, LLC</em></font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ATTORNEYS AT LAW</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1624 Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Denver, CO&nbsp; 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> <p style="margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">William T. Hart, P.C.&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:10%;"></td> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">Email: harttrinen@aol.com</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Will Hart</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">Fax: Fax: (303) 839-5414</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(303) 839-0061</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">July 3, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd. #802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This letter will constitute an opinion upon the legality of the sale by CEL-SCI Corporation, a Colorado corporation (&#8220;CEL-SCI&#8221;), of shares of its common stock, preferred stock, convertible preferred stock, rights, units, and<strong>&nbsp;</strong>warrants, as well as any securities issuable upon the conversion of preferred stock or upon exercise of warrants, having a maximum value of $100,000,000 all as referred to in the Registration Statement on Form S-3 filed by CEL-SCI with the Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We have examined the Articles of Incorporation, the Bylaws and the minutes of the Board of Directors of CEL-SCI and the applicable laws of the State of Colorado, and a copy of the Registration Statement,&nbsp;and such other documents as we considered necessary for purposes of this opinion.&nbsp;&nbsp;In our opinion:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">CEL-SCI is authorized to issue the securities which are the subject of the Registration Statement;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">such securities, when sold, will be legally issued, fully paid and non-assessable; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the warrants and rights will be, when issued, binding obligations of CEL-SCI under the laws of Colorado.</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">&nbsp;</td> <td style="width:3%;"></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Very truly yours,</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">HART &amp; HART, LLC</p></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td></td> <td></td> <td>/s/ William T. Hart</td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>William T. Hart</td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSENT OF ATTORNEYS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Reference is made to the Registration Statement of CEL-SCI Corporation, whereby the Company proposes to sell securities having a maximum value of $100,000,000. &nbsp;Reference is also made to Exhibit 5 included in the Registration Statement relating to the validity of the securities proposed to be sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We hereby consent to the use of our opinion concerning the validity of the securities proposed to be issued and sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Very truly yours,</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">HART &amp; HART, LLC</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ William T. Hart</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Denver, Colorado</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">July 3, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>cvm_ex232.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex232.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><u><strong>Consent of Independent Registered Public Accounting Firm</strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, Virginia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated January 13, 2025, relating to the financial statements of CEL-SCI Corporation appearing in the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024.&nbsp;Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We also consent to the reference to us under the caption &#8220;Experts&#8221; in the Prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>/s/ BDO USA, P.C.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potomac, Maryland</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">July 3, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>cvm_ex107.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<html><head><title>cvm_ex107.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 107</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Calculation of Filing Fee Tables</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>S-3</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Form Type)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>CEL-SCI Corporation</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in its Charter)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 1: Newly Registered and Carry Forward Securities</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security Type</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security Class Title</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Calculation or Carry Forward Rule</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount Registered</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proposed Maximum Offering Price Per Unit</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maximum</strong> <strong>Aggregate Offering Price </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee Rate</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount of Registration Fee</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward Form Type</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward File Number</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward Initial effective date</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</strong></p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Fees to be Paid</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Equity</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Common Stock, Preferred Stock, </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Rights and Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Rule 457(o)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:3%;vertical-align:bottom;text-align:right;">100,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$153.10 per 1,000,000</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:3%;vertical-align:bottom;text-align:right;">15,310</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Fees Previously Paid</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Carry Forward Securities</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Offering Amounts</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">100,000,000</td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">15,310</td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fees Previously Paid</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">--</td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fee Offsets</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">--</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Net Fee Due</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>15,310</strong></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 2 &#8211; Fee offset claims and sources</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 3 &#8211; Combined prospectuses</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cvm_s3img21.jpg
<TEXT>
begin 644 cvm_s3img21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %A N(# 2(  A$! Q$!_\0
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M_0T0_P#@"M'_  NK5/\ H:(?_ %:/[,K^0?7*?F?2E%?-?\ PNK5/^AHA_\
M %:/^%U:I_T-$/\ X K1_9E?R#ZY3\SZ4I.*^:_^%T:I_P!#1#_X K7=?#/Q
MMJ7BZ^OFGU47EM;%8\+;K$"S*S9R.>-OZUE5P-:E!SE:R*ABJ<Y**/7:***X
MCK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THH/2@#!\*_\
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M03&*..;44LIGT^.0 AKD+\F >"V-Q _O 5M^'[[Q9-XB\.R>)OM3Z9'K-O\
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M?2C1H-4327=U+YWFW,K^>P:7<Q/F$="?4C)_.F/--)''')*[I$"L:L<A 3G
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M)<=K&)M8%0RLN[D;AC(]:OZWI,VAZY?:7,XF>RE,+RHIVDC^5=]<3?VW\/\
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M\HZ$C:Q'8DUEZAI5Y>^*O!KV=C)-#/I]@0Z)\AV863)Z#!4YSTQS41K7O?\
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MT0/)&N]PS)WSCN.<9K?VC46VMG;\C/ENT<40RL592K#J",$4*K.X1%+,QP%
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M]XFU7C:3!=,'LS#@]C5*JW:_]:V!P2.,HHHKL,@HHHH **** "BBB@ HHHH
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M#J5RCS1B&1A(<N@& I]1BH;6^O+$L;.[EMRQ4DQ.5R0<CIZ57HHLNP79;O\
M4M0U2X%QJ5[-=S ;0\KEB!Z#TJ2ZUK5[ZT2TO=3N;B!/NQR2$BJ%%'*NP798
M^W7OVV.]^UR_:HMNR;<=R[0 N#[ #'TJ:QU?5-,:1M/U">U,OW_*<C=]:HT4
M6079/]KNL3C[3*?M&/.RQ_><Y^;UYYI\.I:A;3V\]O>S12VPVPNCD&(9)POI
MU/YU5HIV0$D\\UU<27%S,\TTAW.[G+,?4FITU+4(Y+:2.^G1[52D#+(08E.<
MA?0<G\ZJ44607)(YYHHI8HYG1)E"R*IP' .0#Z\@&K;ZSJ\D,,,FIW+1P(8H
MD,A(1",%1Z CBJ%%*R87)%GF6W>W65EAD(9T!^5B,X)'MD_G6KI>N/I>AZI8
MP>;'<7DEN\<\;;3'Y;,3^>ZL:BAQ3T8T[%J_U+4-4N?M.I7DUW-C;OE<L0/2
MJRLRL&5BK Y!!P0:2BFE;1"+]_K.K:J(AJ6I7-X(1B,32%MOTI+76-6LM0DU
M"TU*X@NY,[YDD(9\]<GO5&BERJUK#N]R=[R\DOC?274K79;?YQ<[]WKGKFK%
M]K&K:G<17&H:E<74T7^K>60L4^GI5"BBR["NS;'BOQ UQ;RW>IS7Z02"18;M
MO-C8CU4\$8)_.IKSQ+"^E76G:3H=GI$=[M^U/ SNTJJ=P0%B=JY .!Z"N>HJ
M?9Q[%<S"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^B_
MV;?]3J__ %\1_P#HMZ^=*^B_V;?]3J__ %\1_P#HMZX<?_N\C?#_ ,6)]&T4
M45\>>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E &'X
M5_Y%#2?^O6/_ -!K<K#\*_\ (H:3_P!>L?\ Z#6Y3?Q,F/PH8?XJ^ ;F:"W\
M013W5L+J".XWR0$X$JA\E<^XXK[^/\5?GUJW_'_)_OM_.O:RK[?R_4\[&?9^
M9-XBU#3=4UZ\OM'TM=+L)F!BM5;(C& /U.3^-='X.U&[TCP=XJU2Q?9<6LEA
M(A[9$_0^QZ$>AKAJ>LTJ121)(RQR8WJ#PV.1GUKWY4TXJ'I^!YRE:7,>IZ/J
M7A^R\5Z':>%9"3KNI075XNT@VD8<%;4'N ^YB>X">E9#R:S:>"K*;PJ+E6EO
MK@:C)9J3*)0X\I6V\A=G([$EJX*.22&598G:.13N5E."#ZBK%IJ.H:?(\EC?
M3VKN,,T4A4M]<5S_ %>VJ=_4OVAZ=<7$NG2:SJ#0PQZZGAVVFO1L!\JZ-S&-
MQ'02;=A/HV:IV=TC^ +/48[_ %@7MS>S'4I].C$DK29'EB0]0-O([$[N]><?
M:+C,I\^3,W$AW'Y^<\^O(S4EGJ%]I\C26%Y-:NPP3$Y7(_"I5!VW'[34WO&T
ML,NNP,MK<V]VMK&+HW2JLDLO)\QE7@$KLR.N0<]:[Q9]7F^(O@JZNA<W-A_9
M=JZ-*&:)Y/LIW#/0DD$'Z&O'GD>21I)'9W8Y9F.235@:CJ AAA%].(H23$GF
M'$9/7 [=36TJ-TO1K[Q*=G<['3=5U/Q'X1\36>J7?GH@M9H/,X2W<SJF5_NC
M:Y&!VKI[:WN)+[Q'H%]-KE^EMIUTDC7<:K;,\<99&1<<<J"N"3CVKR!9)$1X
MTD94D #J#@,,YY]>:M2:MJDT<4<NI7+I$-J*TI(48Q@?A4RH7ORZ?T@52VYZ
M'<>(-6T[6O =CI]R;6 Z?I[2+$ OGEC@[_[W''/:N(UW_B5>-]5^PG[/]CU"
M;R2O'E[93MQ],"LIIYF>-VF<M$ J$MR@'0#TQ4EO>7%OJ,=^K![B.02@RKO#
M-G/(/7\:N%+EV)<[G9V,\=Q\.?$3PZM<:CJ5PL4E[;7.0MO&)1^^0Y.]MQ4=
ML!CUJY?KX=\7>()-/T/6=46[:V6*S\Q0MM)Y4( CV]5R$.#GKVKFKOQ4TFG7
M5EIVBZ?I(O-OVJ2U0[I0&#!>2=J[@#@8' J9O&<X\ZZM]&TZUU6>-HI-0BC(
MD(8;6(&=JL02"P&>36?LY:M;_+R+YELR]H U26'3+>ZU!@UVX73K>8Y5<9_?
M,O<+SL7NWTK!UO2ULTL[^.YGGBU /(OVJ/RY@5;:VX>YY![\^E97F2;D;S&W
M( %.>5 Z8]*?<W5U>3>==W$D\F,;I&W'%;*#4KW,W*ZL=WK$GAA/#?A3^V[/
M4Y[C^R<K]EG2-"OVF;@Y4G.<\U'#KWB#5CJ=Y9^&HM3T-_(@ETXQF985B3;#
MT^<$+D;QZFN%>6618UDD9Q&NU QSM&<X'H,D_G4EM=W5G-YUG=2V\G]Z)RI_
M2L/J]EW?_!N5SZGJ6@Z-IEOXG\*ZY#I-UHDEY<7,4NFS.S$HD)/FQ[_F"G<1
MSGD5C::WA^+PQKFI>$[.^;58K<PRI?2JYBM9!MDEC"@9(SM.>@;-<3+J%_/=
MB[FOIY+@=)6D)8?C4$<LL+%H9&C+*4)4XRIX(^AH]B^K_JX^==$=6<^$_"^S
M[FN:W#\W9K2S/;V:3_T ?[57=*;15^$TAUR"]EA_MH",6<BH0WV<]=P/&*X>
M6:6>0R32-*YP"SG)XX%'FR^3Y'F-Y6[?LS\N[&,X]:T=*ZU>M[D\]CM['7]3
MN+NSL?!NCEK/3;:<&SG(G>Z24CSC(.-^?E&U1P%&.E27&CZ?J'AF_P!:D\,S
M^&;S3Y( O,@@NRS[2BK)R& ^;CC -<)'))#(LD,C1NO(9#@C\:L7>I:E?[/M
MU_<7.S[HED+;?IFL?96?NZ#Y^YUWBSPQXAU3XA:[%9Z/=D3:C-MF:%DC +GY
MBY& O?.:R?'-]::EX\U:\L9%F@:4*LJ])2JA2X^I!/XUE3:QJ]Q$8KC5+N6,
M\%7F8@_K5&NB$&K<W16%*2=[=0HHHK8@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KZ+_9M_U.K_\ 7Q'_ .BWKYTKZ+_9M_U.K_\ 7Q'_
M .BWKAQ_^[R-\/\ Q8GT;1117QY[X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !0>E%!Z4 8?A7_D4-)_Z]8_\ T&MRL/PK_P BAI/_ %ZQ_P#H
M-;E-_$R8_"AA_BK\^M6_X_Y/]]OYU^@I_BKX!N);>#Q!%/=VWVJWCN-\D);'
MF*'R5SVR.*]K*OM_+]3SL9]GYF16C'I-Q-X=N-;BD1X;:X2WFC'WTW@E7/\
MLDJ1]?K4OB*^TO4M>O+[1=+&FZ?*P,5H&W>6, 'GW.3^-7O!]S#_ &Q+HM[(
M([+6838RLW2-F(,3_P# 9 I^F:]UR?+S6/.27-8AF\+WT.FR:DT\)LTLHKQ9
MAG#^8VP1C_;#!@1_L&J5YI,]CH^FZE/(@74?,:&+^/8K;=Y]BV0/]TUZ,VB7
M=]X7MOAJK,FNV3)J,J,W +L0\1_ZYHZR>V7JII-]INK>/M3>U\PQZ?IKV^BI
M$BN_[H!59%/!<KO<#^\?6N95GJ^WY=/O-731Y[:V,UQJEKI[JUO)<2)&OF(1
MC<P .#VYJ_<Z!-;66L737",-+O4LG 7_ %C,9!N'H/W9_.NR@OX[FRL?MG]L
M7Q_M6V%K=ZC$J>2X<;U!ZD%>HZ @54U6QOET;QU&;*X$B:W#(RF)LJFZX^8C
M'3WZ5?M7Z?\ #HGD1Y_6IHNBW&M:K#8HQM_.CED261#M81QM(<>O"X_&M;38
M?!,NMZ/'YVI%'O(5NOM?EB(1%AOY49_^M78Z)=^-KCQYJ-IJUK<?94ANP\+0
MX@@7R)!'Y7&!V"[>H-74JM7MVZA&%VKGDT<<LJLT4+R!1EMBEMH]\=*VM#\/
MC5K.^U"ZO&LM/L@GF3) TS,[G"JJC&>A)YX KL1-%I_A;PO_ &->:S;13VP=
MSID"N);K>P=7/4L,* I[8QUI-0U:>UT/QD='^U:5&+VR#P;@I24K()>%X&6!
M.!].U9NK)Z17]7L-02W_ *T//KZUAM7B^SW@NT>%9&=8ROED_P )SZ>O3FJT
MD<D3;9HWB;&<.I4X]>:]9^U2:;HEU?6\4?GQ>$=.:-G0-L8W"#>/<9R#ZU6T
M"XCUZ+P=<^)I_M;#4;ZW26?!+E8HGB1B>"/,;H>.:%7?;^K7#V>MK_U<\P>.
M6,*TD3QAQE2ZD!A[9ZU<TG2Y]6U:PL(\Q+>7"6RS,A**S,!U_'I7<7%\)])U
MN'6CX@OX NV3[; D:VD^X;6!Z@YR-HZ@FM>.X\41?%?3]-T^WE;P^EW"MG#'
M'NM6LPR[7!QMZ88MG.[WI2K.ST[@J:N>4BTD;4OL$?SR&;R1@=3NQ4^JZ3>:
M/KMWHUS&6N;:9X"$4D.RL02O&2.*GBEFM/&"RQR/!+'?<-]TJ?,_2N^U:'75
M\=^,=9NKS4[2*PFE5?)B)GDA:<@>7N'"#NPS@$>M.51QDO3_ ")4;H\M9)%=
MHVC977JI4@CZBE6.1G5%B=G?E5"DEOH.]>Q6Z[]0\(ZO/;74\LNGZDKMJ48\
MR94C8H'P!D8/&><8KF--U;7;[PGK>LV$TMSKQGACFFB7,T-GM;[@'1=^ <=!
MCM5*LWT_J]ANG;K_ %8X)E9<[E*X.#D8P>XISQ31A3)#(F\97<A&[Z>M>MZ:
MLFH)X(?Q9;A9Y+F_*&:,*\[B./R?,!ZDMM W=1C/%8MWJ3OH.N#4FU^^V*,-
M?0+&MI<[AL8$\@YR"HZ@FDJS;M;^KV#V?F<7K&CWFAZB;&]7$GEI)D @$,@<
M8S[,,^]4DBFD.V.&20XW81">/7CM79?$B35I_$R3WWVI[8VMMY$DJML.8(RV
MTG@Y/)Q6C>7/B:P\">#Y_#ZW$4<EO*));*/,C2"XDVJVT9QSP#QUK3VCY(OJ
M_P#(3@N9KL>=*"S!4!9F. %&232M'(LAB:-UD!P4*D,/PZUZOJ$-U:7/B&\T
MBU2/Q2ME9/<Q6Z R0%TS=-&HZ-NV;L<C<WO2:#]NO+SP/=^(HBVJ/K7E0/<K
MB6:U 4_.#R5#D@$^IK/V^G-;^K7*]GK8\I:.18TD:-U1_NL5(#?0]Z3:P(&T
MY/08ZUZ/ILWB2^/B*R\51W']CQ6,SS>?'MCMY%4^08CC ;?M "]03VJ.ZT?4
M+[QOX2FM+&22WGL].<3*G[K"JBN2W08*L#GTJ?;ZV9/)U1QK:3(OAD:X90(S
M>&S\HCY@0@?/ZXJ@T<JQI(\3JC_=9E(#?0]Z]&U'3+K4=&OK.VC*$^+98VD9
M3L@W+@,_]T?7TK0/VB^L/&&FWD^MW_V*QD9C>PJL*RQNNUD7&4.,X )^7/:K
M]O8KV9P-QX=N+#4=.M=3G%I%?6\=TLYC9E173< 1CKV(%8Z1RR;O+B>38,ML
M4G:/4XZ5ZZ9=7O/'?@:2[-U/8-IEJRO(I,1D-NP;!Z;N#GOP:Y^>X\0Z=X<\
M,#P>MTMK/!YDLEE&6,MYYC!UDP.H 4!3V^M*-:3M?<'!?U\C@ "PRJDC@<#/
MTI722-RDD;1N.JNI!'X&O5-4NET*/QI<:1%!!=!].5VC0$6T[(QF\OLI#[QQ
MTYKF/%5U<:EX1\)ZI?2&:]DBN8))V^](L<OR9/<@,1],5K&JY-::/_*Y+A;K
M_5[')B*5H6F6&0Q*<-($)4'W/2FX88RI&>G'6O3=/EU#5K+3]&LY]4\/WD>G
M%%B,.ZRN4",QD8\;=PY+'(S67J.D:AJ&I>#I;&QDFAGTVU"RHG[O*,5?<W08
M(.<]*2K:V8<FFAPXCD9PBQNS$[0H4DD^F/6@JZN49&#KU4J01]17K&J'6+32
MO&L^B0NMS'XC97>%,RQQE7SM[@=,X[5/H*7]UKGA"\UFV5M=N+745(N$ >>%
M;=_):0'WW@$]0!VJ?K&G-;\?*Y7LM;?UO8\@:.2,(9(W0.,J64@,/49ZT>7(
M8C,(W,0."^T[0?3/2N_LY]>U#PSXF3Q>MV;&VMQ)%)=1E3#=[U"+&2.I!8$#
MM]*VII/$47Q#L](TNVD?PP3$D$ CS:2V1 W.QQMP5)+,3D'/>I==K2WXB]F>
M3!78C:C-G.,*3G'6KVK:1>:-/!#>+@S6\5PIP0-KH& Y[@$9KK]5U-M(\"6E
MOH$WE6MSJ6H1+<!?WDD ,>U=W7!!!([UN_Z9J'C[0)=8^TSVO]CPR6;3)NC>
MZ^R H%+?*S%P.,\D4>V:UMIK^ <BV]#R:2*6+;YL3Q[AE=ZE=P]1GK6CH6BW
M&NZ[I^EQL8!?3"%)W0E ?ZUV<E[!=:)J,6N2:]?VOGQ(TU_"J"TE,@R0>N2@
M<%1Z\]*Z#2[GQ8OQC@T\6\PT:.ZVPPK%FU2U&?+9#C;C&TA@<DGUI.O)1>FN
MHU35T>6:+H\FM:J^GQ3+"R6\]QN89&(HFD(_$+C\:S3'(JHSQ.@D&4+*1N'M
MZUV'PY$P\>@11K),+.^VQR#AF^S2X!!]ZOVESXBO?"GB4^*?M0M+:%9+:2[C
M*&*\$BA%CR!@E=^0.PJ75E&=NFGXDJ-XW]3S_:V[;M.[.,8YS2=*],E$2^=\
M3(T01SV6$4#A=2?,3@#V^:7\17.^!(]VNW;01I-J<5C-)IT;@-NN0!MP#P6
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M_P#?2_XT7HW^-6]1VJ6^%E2?Q!X;U2>/5M=T6ZN=66-4E6*X"073*H57<8W
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M9CV; /;M["J6KZJFIVND0K"8SI]DMJQ)SO(=FW#T^]^E=+_PJ3XB?]"K=_\
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MMW_WTG^-'MZ7\R^]![.?9G"T5W7_  J3XB?]"K=_]])_C1_PJ3XB?]"K=_\
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MR4?\+HU7_J!?]_9*/[.Q';\4'UJEW/<J*\-_X71JO_4"_P"_LE'_  NC5?\
MJ!?]_9*/[.Q';\4'UJEW/<J*\-_X71JO_4"_[^R4?\+HU7_J!?\ ?V2C^SL1
MV_%"^M4NY[E^%'X5X;_PNC5?^H%_W]DH_P"%T:K_ -0+_O[)1_9V([?B@^LT
MNY[E^%%>&_\ "Z=5_P"H%_W]DH_X73JO_4"_[^R4?V=B.WXH/K5+N>Y<T<UX
M;_PNC5?^H%_W]DH_X71JO_4"_P"_LE+^S\1V_%!]9I=SW+FCFO#?^%T:K_U
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M50@KZ+_9M_U.K_\ 7Q'_ .BWKYTKZ+_9M_U.K_\ 7Q'_ .BWKAQ_^[R-\/\
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M6#W]ZT]B[;_U8/:*YW<TFAV&G^)=4T_3;>YFBBL'59K4QQPW#E@[+&W\)^\
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MM@',:J H1D/WDV@#&>PJWXF\31:EH=KHT%]=:CY=R]W+=W*"/<Q0($1 3M4
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M@)_A8CC-9?C;QQHO@/P\NN:VMP;1KB*U'V>,.V^0X7@D<4 =9129!/!!I>]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH ****8!1112 **** "BBB@ HHHH **** "OHO\
M9M_U.K_]?$?_ *+>OG2OHO\ 9M_U.K_]?$?_ *+>N''_ .[R-\/_ !8GT;11
M17QY[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 8?A
M7_D4-)_Z]8__ $&MRL/PK_R*&D_]>L?_ *#6Y3?Q,F/PHC;[K5\ 7EK<7NN+
M9VL1EN)YC'&B]68M@#\Z^_V^ZU?G[J4CQ:HTD;E'21F5E.""&X(KVLJ^W\OU
M.#%?9^8S5]'U+0=7N-)U:U-M>0$"2(D'&0".1[$5UG@32-"U;0O$JZVJ1MLM
MH;6[;_EUEDD*J_\ NYP#[$UQ=U=W5]=R7=[<27-Q(<O+*VYF/N:U]+U:TM/"
M'B+2IM_VC4?LWDX''[N3<V3VXKW*BDX6ZZ;>IYL6E*_34Z/P'X5M3XK+^*K/
M-G9WJ:>UH_'GW3G:(_<*,N?8#UKDM1TE[/3+75/,4Q7EQ<1)&!RGE%0?SWC\
MJW[;QU>WGB3PS>:VP^RZ/-&[^2GS2D$;I&_O.551GT45!'?^']4\.PZ9JM[<
MV$]C>SW$3Q0"431R[<KU&U@4&#R.:XU[12YI?UN6^5JR_K8L6>@QZ?IWB2.[
M$5S*NAV]["^W_5F22$C'N Q&?K5EM!TL7/@1=)N(6O\ 48X]Z3VN8Y7-S(N]
M^>0,!<=PM2R^)/#5[JFI1F2[L;#4-%@T]7,8E>!XC'U&1N!\OKQUJO8:]X>A
MD\'ZA->72W.@R)'-;BW!62,7+R[PV[KM?ICJ.M0_:/76_P#P/\RO=_KU(+K0
M9M0T#P_;Z?:1?;9KB^\Z4 (H5)%^9V[*HSR>E&G^%Y=6M;/3=/OK2:"ZUL6$
M=UY)#LYB!W9Z[/0>O-3P^/'T[0=-TVP021+=74E];R( MS%*PQ&3UP5SQV.#
MVJQHOB;PYH5SID=L]W)9V?B!=2!>,;Q!Y07;UY8'CWQFM?WB3LN]A>XV8ESX
M5@BT?4;NUUZVO;S2PKWEK%&V$5F"95SP^&(!X'7C-._X1&%+V+1[K7K>WUR8
M+MLFC.U78 K&\F<*YR.V 3@FJ6D:K;V.G>(89=XDU"S$,!5<@.)XY.?080UU
MUYXX@U+4#K<OB'4K*1U#RZ=!"I/F@8.R0GA21GD$C-.]5:?UT_X(DH,\YDAF
MBD>.2%T=&*L"I^4C@@UTEUX-N+:VTS&HP37VJPV\ME8QJ3)*)<=>R@'C)ZX-
M4U\6^)TLY[--<NUMK@NTL0D^5RY)?/U).?K6C/XJCM_$7AC6M-C+R:/9VD3)
M*,!I(A\P^A]:J3J="%RE:3PS:R&[M=,\06^H:E9QO)+;1Q,JN$&7\IR?GV@$
M]!D XJWKVF:>VO:3;?:K?2H)-'LYI)60D%C I)PO)9C^9J_?>*H4AO+BP\4Z
MK(TZ.L%H85C,6X8(>3/S  D< 9]J?'XD\.M=6=_]LN;:\;1XM-\P6P8V$L:J
MHE4Y^;(4CL0&/I6/-4YKLTM'8JZ3X5L1XD\-32:@+[1M1U!+9G:W9&WADW1.
MA/&0R\Y/!]JS'\/V<^HZM/'JJ6^C6$FV2[DA(.YF(6-$SEFX..>@)XK>;QAI
M\-GX>ADU&_U:?2=:74))YHPOF1X3*J,DC&SOUS4=GXCTG2Y-9TO3]:O4LM2E
M2ZCOUM@KPRJ7^4IN.Y2KX/(.:=ZF_P#6_P#D%H&/#X/N+Z\L!I&H07EA>^85
MO&!C6#RUW2>:.=I5?F[Y!&*T[30]&C\)>*KVQU:WU<6]M"JL83%)$YG0;E!S
M\I&1G/U%2+XRAM=3MH+C4K_6=-:WGM[PNHBR)DV,T2\X(&.23DBJ<5WX6TCP
M_K^G6.I7FH7&IVZ1Q2M;")(]DJN%(W$DG!YZ#'3FMFZCM?R_/_(2Y?Z]#F]-
ML[6]NS'>:E'I\2J6,C1M(6_V54=6/X5MGP9=3ZCID.EWT5W::DLCQ74B&$1"
M/_6^8#G;L')Z\$8ZU%X5U6QTW^TH[FXDL+BZ@6.WOXH_,:V8,">,CA@-I(.1
M72MXWTR.VT2UFN+_ %9;3[;;7LLRA'FAN$524Y.",' .>GO6DY5%+W5_5O\
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M!M-+G++Y+1E7&,21[OO 'OP?:N$KM+&X\'Z+%J_V/5-0O6O[":U@#VPC\C<
M1O\ F.XY '& .M<76M.^MR)6L@HHHK<@**** "OHO]FW_4ZO_P!?$?\ Z+>O
MG2OHO]FW_4ZO_P!?$?\ Z+>N''_[O(WP_P#%B?1M%%%?'GOA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %!Z44'I0!A^%?^10TG_KUC_P#0:W*P
M_"O_ "*&D_\ 7K'_ .@UN4WNR8_"B/\ A:OS[U;_ (_Y/]]OYU^@AZ-7Y]ZM
M_P ?\G^^W\Z]K*-Y_+]3SL7]GYF?1VZ>U%=AX;U"?2O#'B/4+-46[CO+)8IF
M4,T)(F!9<]#C(_&O?G+E5T>;%79R*H[%@L;-M&6PI.T>I]*1%:1@L:-(QY"H
M,D_E7J(GBLO"WAZ?3M7U>S^V0M+<2:=9B7SKKS&WB1LY+ ;<*>Q'K3)-3L[/
M4=<CLK'6-&CN+B'=J%E;+YD,RQ_O(F09 5F);:",<5S>V?1?U<T]GYGF*AF8
M(JEF)P% R2?I6AHVDS:UJAT^&189!#+,2X/ CC9R/KA<5WU[;ZWHFF:]>6-T
MU[K_ -JMQ<7D,.)H[5X=Z,%ZH68@-W! !ZU=TU;JZOO#E]JL++K]WIVI+*"F
M)9X1"XA=UZ[C\X'<@"JE7]VZ_K2XU3UL_P"M3R/G R",\\TJJ[.$5&9ST4*2
M3^%=WHFD#Q7X?T^SN%,,NA7)2]8KM9+%\N6/^XRN/^!BM:RU*TO_  WK?B2W
MN;S3KZ?4PDK:?;"66WM?+_=(.053(P2.Z@&G[:VEOZZ$JG<\MZ$@\$'&#US6
MC#I,\NB:AJA81K8R0Q/$ZD,3)NQ_Z"?SKTJ!X+B[-Y96UW=>*(-'FFMI+ZV6
M)[EO,4)(J9.Z18S+@GD[5-8DMYXBU#X6:Y<:Y'<2A;ZT6.YN8R)&_P!9E<D9
M(''L":CVS?3JOS'R6. 56D?9&C.W]U1D_D*U-!T677+Z6!9UMH+>%[BXN&0N
M(HT')P.2>@ [DUN>'1?:;X7N-:@U*_MH9KL6OEZ;&#*7";LLV#M7#<#N<^E=
ME=S7FDZ]X@GL9KFTENO"<5Y*=OE.TW[H%V X#9)S[DT5*S3<8A&'5GF>HZ#-
M8Z7#JT-P+JPN+B6WBE$;(6,80DE3T'[P8Y[&LG:WE^9L;R\[=^#MSZ9KOYK[
M4[[X;:!'>7EY+I[ZM=+>,-S*(\6[?-CIC+$9]ZZ2_N+6U\8WNGS3ZS<Z1#O4
MZ7%8+]E-J <%3NQC;@A^N>>M9PK-+57W_!C]FGMY'CF#Z'IGIVI55Y'"1HSL
M>BJI)/X"NS\1:I<VO@_P[I=D1#:W6G%YBJ@/.!<2[0Q[@8Z5%X3U$V&C:BC1
MZI9K<31A=5TZ+>\)4,?+8?W6R#@$'@5T^T?+S6(Y5>USC^<'@\<?2EP?[IY]
MJ]&UC2]2C\/>*;:YE;5+Y;O3KIIHX2',3QR89EZJ?F4,.Q-:6DV4NG/X 6]L
M5$OV'4Y6AF3.[B5@''TQP><&I==6O_6URO9N]OZWL>3JK,RJJLS-]T 9+?3U
MI#D9R",<'/:N^TO5];NO"FMZ]8223Z^L\$,DT,>9;>TVM_JP!\J[]H)'08'>
MNATZ)M3M_ TOBJW"SSW5^0TT0#7#K''Y.\'&[+[1SUXI.MR[K^K7!4[[/^KV
M/(F5U"ET90PRNY2-P]1ZTF&Y^4\=>.E>BZA?1W'AW78]4N]=U0+%A1>V*Q+:
M7&X;&#$_+W!4=0:M^*/$S:?\5[JPO$1="BF,,]K&@"LDD861_=L,3GU IJK)
MZ)=_T#D6]SR_GT/'Z4E=GX@TN3PCX<?0I]K7NHW;3.XYS;1$K$1[.Q9OHJUQ
ME;PESJZV,VK:!1115B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** -&;7M;N-/&GW&K74MH!@0M*2N/2LZBBDDEL%[A5AKZ\DL(]/>ZE:TB
M<R) 6^16/4@>M5Z*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY[ZA_P!_1_A2?\,\^"/^>^H?]_1_A2_M'#>?W#^J53YDT#4K'399FNOM\$K
M>5=6$WER1>HP<AE/]!5CQ#XA35+6PT^S6Y%K9-)*);J3?--+(5W.Q& /NJ !
MTQ7TI_PSSX*_Y^+_ /[^C_"C_AGGP5_S\7__ ']'^%1]?PW-S:C^K5;6/E>\
MU?5M0A6&^U*YNHTY5)9"P%1I,EUJ2SZM-<31NX,[JV9&'?!/?ZU]5_\ #//@
MG_GMJ'_?T?X4?\,\^"?^>VH?]_1_A5_VCAUM?[A?5*A\P^)-9.O:]+?K$88
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M]_\ ]_1_A1_PSSX)_P">]_\ ]_1_A1_:>'\_N#ZI4/DJBOK7_AGGP3_SWO\
M_OZ/\*/^&>?!/_/>_P#^_H_PH_M/#^?W!]4J'R517UK_ ,,\^"?^>]__ -_1
M_A1_PSSX)_Y[W_\ W]'^%']IX?S^X/JE0^2J*^M?^&>?!/\ SWO_ /OZ/\*/
M^&>?!/\ SWO_ /OZ/\*/[3P_G]P?5*A\E45]:_\ #//@G_GO?_\ ?T?X4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cvm_s3img20.jpg
<TEXT>
begin 644 cvm_s3img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" (0 A8# 2(  A$! Q$!_\0
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M7%I:7;1LTMMMWC8X88W CJ/2MNPTNWL/#]IH_,UM;6R6O[T ET50OS=N0.:
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MDC.X8.2?6JMK^SWX7L_ ?BSP;'KFLR6?B>Z2ZN)YY4DFC96###%><D<ELDT
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M%E+?Q,9(5;<J.KLC8/IE21[&JL?PQTB/QEXL\5+?WGVGQ/8)87$7R>7"BQ[
M4XSG'J2*U_ /@O3_ (>^!=.\(Z7=7%S:6 <)+<[?,;<[.<[0!U8]J .JHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+98]H<9&X%HAG!'!K4L?#>O3>--%\5Z]?V#WEEIMS8SQ64+I&[22QNK+O8D
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M<,'?^%1]U/I[^]7* *VZ^_YXP_\ ?P__ !-&Z^_YXP_]_#_\35FB@"MNOO\
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M_P#?P_\ Q-6:* *VZ^_YXP_]_#_\31NOO^>,/_?P_P#Q-6:* *VZ^_YXP_\
M?P__ !-&Z^_YXP_]_#_\35FB@"KNOO\ GA#_ -_#_P#$T;KW_GA#_P!_#_\
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MO^>,/_?P_P#Q-6:* *VZ^_YXP_\ ?P__ !-&Z^_YXP_]_#_\35FB@"MNOO\
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M7ER7)W3?)'VB]?\ >_PH 3S)+GY8?DB[R^O^[_C4L<20KMC7 [^I/J:L=J*
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M4T* 20 ">OO0!6AM]K^9*WF2_P![LOL!VJW110 4444 %%%% !1110 4444
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M-<_Y%_4/^O=__037F1W1U2V-,=**!THH*"BBB@ HHHH **** "BBB@ HHHH
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M_P!\K_A1]GF_Y_)/^^5_PJQ10!7^SS?\_DG_ 'RO^%'V>;_G\D_[Y7_"K%%
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MY_)/^^5_PJQ10!7^SS?\_DG_ 'RO^%'V>;_G\D_[Y7_"K%% %?[/-_S^2?\
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MQ!_U^R?SKW\C_P!X?H>/F7\./J<O129HS7Z$?."T4F:,T +129HS0!RFK?\
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M[LWW5_Q^E6Z* *L,*Q MDN[?>=NI_P ^E6J** "BBB@ HHHH **** "BBB@
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M7S)?[O9?<GM2?93C=-<2LQZ[6*@?0"I8XHX4*HN.Y/4D^IJ>@"K]C7_GM/\
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M#_A/3_''AJ#PO)H&IV]HUC9WZW+W\\\X!$2B,A">?4< UO\ B;X%^%O$E_\
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M_%7Q)\1S_P 7/\0?]?TG_H5>_D7\=^GZGDYC_#CZG*44F:,U]V?/BT4F:,T
M+129HS0!S&I_\A.;ZC^0JGFK>I_\A*;ZC^54Z\&I\;]3T8?"CVW]F7_DK4__
M &#9?_0DK[/[5\3?LYZA8Z3\3+B^U*Y2UM1821F63A0Q9,#/KP?RKZV_X3KP
M?_T,5E_W\KY/,?X_R/:PO\,Z6BN;_P"$\\'?]#%9?]_*/^$\\'?]#%9?]_*\
M\ZSI**YO_A//!W_0Q67_ '\H_P"$\\'?]#%9?]_* .DHKF_^$\\'?]#%9?\
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M$'C@'OP.IXKJ*X?6-6\12ZS>:;H-CILT&GVJ3W0OB^9M^[$:;>!PAY.1R.*
M,CPKX@N[W6-,L8]:75BK:A'=-^[9A%'-MAD)0#&<8'0$'..*]/K@?!\=]J,L
M6O6NGV^@:)/$);?3X(D$MSN7B69EX'!^51]2>U=]0 4444 %%%% !1110 44
M44 %%1R2I"F^1L#^=5O+DNOFF!2+M'W;_>_PH :TLEQ\MN<1]YO_ (GU^O2I
MTMX8UVA ?4L,D_4U.  , 8 I: /G']H)577-$VJ%_</T'^U7BM>V?M"?\AS1
M/^O=_P#T*O*M!\/ZUXBOS9Z+8O=2+C>PX6,'H6)X XK[O*JD88>,INR2?YGR
M6-BY8B2BKO\ X!D45KQ^'=6F\3R>&8H4?4XY'B:/S5"@J"6^8X&  >:O:QX(
MU_0M(_M:[BMY[ /Y;3VMPDR(WHVT\5[3QM!247)7>VNYQ^RG9OEV.:HKI]0\
M"^)--T)M:O+.-+:-$DE19E:6%'^ZSH#E0:RM0T>^TNTL+B^C6);R'[1 F[+^
M7G 8CL#V]:J&+HS^"2?S)E3G'XE8S:PO$/2W_P"!?TK=K"\0]+?_ (%_2M:_
M\-E4?C1@UK^&.?&.B@\C[=!_Z,%9%:_AC_D<-%_Z_H/_ $8*^8Q'PL]>&Z/T
M7\F+'^I3_OD4>3#_ ,\4_P"^14@Z"EKXH^B,AHX_^$F4>6N/LA_A_P!L5H^3
M#_SR3_OD51;_ )&A?^O0_P#H8K2_B-#Z"749Y,/_ #Q3_OD4>3#_ ,\4_P"^
M14M% R+R8?\ GBG_ 'R*/)A_YXI_WR*EHH B\F'_ )XI_P!\BCR8?^>*?]\B
MI:* (O)A_P">*?\ ?(H\F'_GBG_?(J6B@"+R8?\ GBG_ 'R*/)A_YXI_WR*E
MHH @\F'_ )XI_P!\BOB7XC<?$[Q&!P/MTG\Z^WZ^'_B0?^+G^(O^OZ3^=>WD
MO\9^AY69?PX^IR=%)FC-?=GSXM%)FC- "T4F:,T >N^$O^13L?HW_H1K<K#\
M)?\ (I6/^ZW_ *$:W(S$US%#+<16XD8+YDS;43W)["OS/%_QY^K_ #/KZ'\*
M/H@HK9\3:+#X=MK"<:@EXMY$9-\:X3M]TYY!SUJ[I/A_1=:F:STWQ()[U8O,
M8+;-Y0QU&_-<IL<S170:+X?M-2L8;J[U9;3[5=&SME6,R>9(/4Y&!59M$:#3
M+^\NY_+:WN3:1(J[O.D!^;'L!WH R*\\\5?\C!+_ +B?RKT/H<'@UYYXJ_Y&
M"7_<3^5 &'7H_P %55OBE8AE!'E3=?\ KF:\XKT?X*?\E5L?^N4W_HLT ?5/
MDP_\\4_[Y%'DP_\ /%/^^14M% $7DP_\\4_[Y%'DP_\ /%/^^14M% $7DP_\
M\4_[Y%'DP_\ /%/^^14M% $7DP_\\4_[Y%%2T4 %%%% !7,:KX+\/ZUJ3ZEJ
M%K.;F2-8W>*ZEBW*,X!", >I_.NGHH Y71_!/A_0;J.YTNWN(7C0QHK7<KHJ
MD8QM9B/TKJJ** "BJ-K>6MU;&YM;B.:$,R^8C KE20PS[$$?A5;3/$.AZQ+-
M%I6KVE])#_K%@F5ROUQ0!KT5D:?KFCZM<7%OINJ6MY-;';,D,H<QGISCZ&KE
MK>6]Y:I=6DR3PR<K(ARK<XX- %NBBB@ JI-<;'\N-?,E/1!V]R>PIAEDF)2U
M/R]&E/(_#U/Z5-%"D*D+U/+,>2Q]30 D=N0_F3-YDG8]E^@JS110 4444 ?.
MO[0W_(<T3_K@_P#Z%7F_PSL]:N/BCI$VGPW4MI;W"O>-!G8B$'!?';/K7HW[
M0W_(<T7_ *]Y/_0J\,3[7!,TEI>SVQ;[QAD9,_7!YKZ[!TI5<)&G'=I_F?,8
MB:ABI2?3_([CQUX6\1:I\3]8L[#3YA=7L\\]JK'R_M$8Y)0D@'C\ZZ36K>\C
M^ 5['J7A]?"$\5^C06,/RB^/RC+*V6XY/7^'/2O);B2_N9(Y9M0N9)8_NN\K
M,R_0DY%*7N9<&ZNY[EEZ&:1G(^F36KRVK-P4FK1M^'S)6(A%2:6]_P 3U/1?
M&6G>-M1U"SDT6>RN=2M(AK=\]QN@BM;<9=D7&06 V\^M;&EVNC^.8--UZ3P^
MFI0:O<7,-U.967^RH(E(A48("_* >>I->)*KIYGES/&LB[7",0''H<=13;9;
MBU$B074T44GWT20JK_4 \U3RJ2E>G+E^_P#S$L2FO?5R[<I''=SQPR>9$DC*
MC_WE!X/Y5SOB'I;_ / OZ5M5A^(#Q;_\"_I7T=3^"SCI_&C"S6MX7_Y''1?^
MOZ#_ -&"LBM7PN?^*RT3_K^@_P#1@KYVM\+/4ANC]'QT%+2#H*6OB3Z(RV_Y
M&A?^O0_^ABM+^(UFM_R-"_\ 7H?_ $,5I?Q&A]!+J.HHHH&%%%% !1110 44
M44 %%%% #:^'?B5_R5'Q'_U_2?SK[BKX<^)1_P"+H^(O^OZ3^=>WDO\ &?I^
MIY69?PX^IR>:,TF:,U]T?/BYHS29HS0 N:,TF:,T >O^$O\ D4K#_=;_ -"-
M6M2MH[R2&W:ZBMO,<+YLS;43/=CV%4_"1_XI.Q_W6_\ 0C6R=-DU+<L5M+<;
M?O>6A;'UQ7YIB_X\_5_F?7T/X4?1'6>+O[)N_"6CK;Z]IUVVFVJP2)#/N9V^
M4948Y'!]*/"<EGX=N9HY_'&FWWAYXW9K!.979AT*8R#^-<7]AA2,PE< <8/:
MB&RMX&W(O-<IL7--\2ZUH<CV.FK9BSDNC-;B\B#BV8G 923\N!WKKK3Q9IT?
MB"]TBWU:"W%M8M#8ZC/_ *M[ECNEE)P<;B>OH/>N.FM6:..:6%Q&^=CE2 V.
MN#WJL]E;NX<J,B@#K?%E]9W^M1S6=Q'<LMO&D\\0PLL@'S,/6O'?%7_(P2_[
MB?RKT2*UG:SDN8H7:WA(5Y ORH3T!-><^*C_ ,5!+_N+_*@#$S7HWP3/_%UK
M#_KE-_Z+->;%J]&^")_XNQ8?]<9O_19H ^LZ*** "BBB@ HHHH **** "BBB
M@ HHHH *H7UE;ZC9RV-Y'YEO,NUTW%<CZ@@U?JC>V=OJ%K)9749D@F7:ZABI
M(^H((_"@#S*PCDM?V>M6AL%:/RH[Y$"9RJ":0'_QW-;5]#:+XV\&0Z=L17L[
MJ(F' _T?REQT_AW;<>]=!H_AG0]!AGATG3Q;PW'$D9D9U;KV8D=S]<TFD^%O
M#^A7#W&E:7%:RNNTLN20N<[5R3M7V&!0!PZZ#KVE/IFDR2V<$[6)T:UDLW9G
M>'<KRW#@J-I5$X )^=^O-;'A'Q%=75YI>GR:?:6NG7MB]SIZ6[LSPQ1LJ;),
M\9PR\CT(KM#9VQU%=1,*FY6(PK)W"$@D#ZD#\A6=IOAS0]'O+B^TW38K:XN"
M=[IGH3D@9^Z"><# S0!OU3DA>:7;(V(?[B]6^I]/:KE% #0 H 48 ["G444
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M55^W6W_/8_\ ?)_PH^W6W_/8_P#?)_PH M455^W6W_/8_P#?)_PHH M4444
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M\4Y:?1O_ $(UK;J_-\7_ +Q/U?YGUE#^%'T1+NHW5%NHW5S&Q+NHW5%NHW4
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MU>7$UZ9\"9-GQ>T]MK-^YGX49/\ JS0!]D456^U_].T__?%'VO\ Z=I_^^*
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M!\?:'(JZ);*SJ#@\%@.YK1\V/_GHG_?0KZO_ .$%\(_] "T_[XI?^$%\(_\
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M5 [DA3@>M8\,UCXP\=0WEG'+/I-MI<]K<2R1/&KM,R?N_F )(5"3Z9%>B44
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ME\+ZQ:Z/IWA&XU#4Q9Z;+IMTBR7$NR-Y/-0J"3QNVAL9YZUZN8XV559%(7D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_s3img19.jpg
<TEXT>
begin 644 cvm_s3img19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" '] CT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *H:FS1:1>31L5=('96'4$*<&K]5[B%+BUEMY,[)4*-CK@C!H ^
M1?ACXP\>:O-X*O-)\2>+=<O;NXD&OPZA:DZ=#;#=ETF* !AA<88Y.?H>U^%O
MQ8\6#2_!5AXIT=[VQ\0WEU8P:S)>!YGF1Y"-T>.$PNT'.>.E>R^$_".D^#O!
MEGX3TEISIUI&T<?GOODPQ).3@>I[5@V/PE\*:?IOAC386O6@\-7DM[9!Y@2T
MDF[<'./F'SMQQ0!RFB_'634OB!8>'+K0;9(-3N+JVMVM+];B:-X02/,"C9\^
MW@*Y(R,U!X4^/D>M7FL?VQH<.EQZ997%[-;?:_\ 3+<1'[DL+JIRPY!7<!W(
MK>T;X(^%-#U/2+RVU#6YHM&FFFL+2>]W06WFAMZJH4<'<>IR..:LZ;\'_"]C
MJXU&\N-6ULQVD]A;PZG=^<EO!-Q(B\!B"./F)('2@#&^'?QM;QMXEM='NM"6
MR&H637UK-;3/,L8&"8ILHH5\'/!(X/-8OQBU/QWX5OI?%&F^-+^WLOM5M#:V
MMK:1M8V*942O?.06PV3@C&/;K7H'A+X7Z+X1U2WU"SU;6[TVEL;.S@U"^,L5
MG$3]V-<#T RV3@ 51\0?!7PGXFU_4M5O;O6+>+5I(I-2T^TOFBM+]H\!3+'C
MG@ '!&<4 9_QD;QXUKX>D\+MJDND"9WU>'0)HXK^6/9\IA+YR >2!R>*\^7X
MG>,--\ Z#-X0UI_$\\GB==(NFU^'[)>6VYAMM)EP?FZ@R=O3->U>,/AYH?C1
MM+NKRXU#3+_269K*_P!,N3;SP!AAE#8/RD 9!':L@?!7P;_PATOAOS-5_>ZB
M-6DU(WC&]>[!R)C*1][\,4 9VM?&*YT73?B-<W&@HTW@I;/=&MQQ<-/$KD9Q
MQM+8]\5S?Q*^+'BE]!\=6'@_0VCC\.Z?"U[JHO!%+;S31B1?*3!W[5(R<CVK
MK?$?P-\(^)K[5[O4-2UZ/^V8(8=0AMM0,<=V8E"I)(N,,X"CKQ[4_P 2?!/P
MGXDU#4[J:]UBR&K6T=MJ%O97IBBO!&NU&D7!RP  STX&0: ,'_A<UUHNC:AI
M]]HIN]>LHM+73X3/@ZJ;M557!Q\IW[P>OW:=\:M<OM)\0^ ;'^WM<TC3M0N;
MM+XZ"K/<2!(-R!5"L3A\=CQFK=U\+[S4OC=X<\37D-E%H/A:R$%EMD9[B\<+
MA#*,!0$)8@\\GM7H&K>%=,UKQ)X=\17WG?;= EFFM!&^$+2QF-MPQS\IXZ<T
M >->%_B)\3K70-'\.S:&-4\2W%K?:HLFN,;.0Z?#(%B,BJIQ,^X#&!CJ:N3?
M'+Q%J5FEYX5\*V-S;CPR/$DOVV[:-E0,PDB "G+?*<'IZUZ'XQ^'>C^-;VTU
M"\NM2TW4+6&6V6[TRX\B5H9/OQ,<'*G _'D5Q.H_ VSU+QGM2\NM)\*1^'8]
M%C@TVZ,,KJ'):-^"&1E//?- #K[XX7$.B^*M5L=!ADATC1--UBW668@S?:\D
MHV!QM]1G-&G^.=:T_5_BIJ%S?VTL.DR61L8=2N_(MH#)"I*[\$@%F[ DG@<F
MMOQ%\#?!_B!YVDFU73X+BP@TV>UL;PQ130P?ZD,N#DKV[>H-6-6^#OA'7+C6
MIKJ;4H1K*6PN4@NMJ^9 5,4RC!Q(-H&>A':@#S75/C%X\U6WT(>'X=,MKF/Q
ME!H%XX,@BNU>+S$ $D>]$8$[C@,"HQD&NAD^)FJZ-/XDAM;-]2U6X\91^'=.
MAO+PF!))($?.0N8XP QVC)S]:Z:3X+^&9-,NK6:^UB6XN-7BUTWS78^T)>1H
M$616"@#@=,8Y/3C%N]^$OA6_L]6MY&U".34]637#<Q7&R:VO%5562)@/E("]
M\]3ZT <7_P +B\37!TO2;/PU8MXAGUZZ\/W<,EXRV\4T4?F!T?;DJ00>F>U6
MM4^(&L:]^R[XB\9VL?\ 8>L06MW'_HTI;R9H96C+(V <94D<=ZZG3?A+X7TU
MM#DA:_DN-'U";5%N)KC?)<W,JE7DF./F)![8Q@59B^&OA^/X:ZC\/5:\_L>_
M^T><3*/-_?2-(^&Q@?,QQQTH \9TOXJ>*#XJ\&Z'K%Y)'KFCZ?K UNS!^2]:
M*UBEMIR.ZNIW ^N[TK6^%OB[QJWC;P?;^(/%$VNVOC/P_)K#P311JMC,K!@(
M]H!";6"X.>1FO2YOA;X3N/'FF^-)+67^UM/L6TU6#@)/"4*8D7'S$*Q&>/T%
M8=K\$?#NA:7K,?AR_P!3CU"[TZ33+&:ZOG8:9"[%MD! S&NXYXYXQF@"Q\=(
M=3M/A'K7B#1_$6J:-?:/;O=1-83",2MP-LF0<K[#%>5>,M0USP[XA\'Z#)X\
M\:S6U_H=SJ#26'^DW4MS\AC!5(SE 3TQ]37OM_X-LM:^&S>!]:O+J[M9[%;*
MYN0^)I0% +;CGDXSWH7P/HZ^+M'\4!KG[?I%@^G6X\P;#$V,[ACD_*.<T >*
M:7)\2/%7C'P?X:\3>+=:\,ZC+X5:_NUT]DB8W F*J\B%2,[=I9>.<CBG>"?B
M%XP\0>(?AK:ZIJ[2/)>:MI^H/" D>H&WX24J./0\<9S7J/B[X5Z+XP\26_B"
MZUK7=*U&&T-CYFE7QMM\);<58@$\D^M4M3^"?A&^TOP[INFW6K>'X_#JRK8R
M:1>&WD3S/ODO@DECDD]\F@#*^)&M>.M$^(_@;^S]:@M/#>HZM#8RVD<.9YV9
M6+;W.0$P!@#!SG)KH_B%\0)/!::9#%I\;SZE*T,=W?3?9[*V8#@S38.W/8=_
M6L_Q!\'='\3#0QJ?BCQ2&T1$%K)'J6&\Q<XF8E23)@D%J]%:T@ET\V=T@NH3
M'Y;K. XD&,'=G@Y[T >)?%35/B5H/@SPUK5GXHTNWB:^MHK^33[<DW1EG 58
MV8D+&$/)ZL>>*R/BMXT\;6OBOQM-X?\ $\NCVW@G2K._BM$B1H[Z260[Q+N!
M)7:-H (YKTGQ3\'_  OXIT/3] :ZU+1-(TZ0RPV.D7 MX0^_>&*[2,AB2,8Q
MFJ^O?!/PAXFNK6ZU>\UB>2.UAL[O%Z5&IQ1-N1;G _>889SQ0!Z+IMY_:&D6
M=]Y>S[3"DVP_P[E!Q^M7JC551 JJ%4#  & !4E !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 57GGCMK:6XF;;'$A=CZ #)JQ5/4+47VEW=BS;1<
M0O$3Z;E(_K0!Y_:_$Q8=#T2XU+1[^\U+6;.?48+338!(5@C9,Y+, "%D0\D9
MYQS@'5;XA:!'9V%ZW]JSP:A:I=PO::1=W*[&SC)BC8*W!RI.1^(K&\+^%-2G
MM?"NH7V;&;1]$N]%FMI(SN9W:$!P?[N(,^^X5?TWX8^'U\-:3IOB"SCU2ZTV
MS2S^T!I(PRKD\ -ZDT .U[Q=K6E^,/#&GVFAHVCZO<K;R7T\I1P6B=PJQ8R"
M-G);&,XQ2S^*M=A^*^G^%9M#BM])O+:XEAO6GW2S-%Y9.$'"K\^.3DXZ"F>+
M_"_B;5]9\-S>'[W2;2QT6X6[5+N&5W=PCQ[<JP 7:X]\BDU?P[XNOOB5HWB2
MWOM(CT[3(98!!)#*9G641^8=P; (*?+QWYH CF\=7$GQ;T_PEIUBDVF.)X;N
M_9C\MRD8D\J,=#M7&X]BP'4'&QX^\0W'A/P1J'B"UA6:6U:'Y&4MD-*B'@<D
MX8X [XKEK+X2QZ3XI\.ZIIOBC6OL>CS7,QL[B=9!(90<X.T'EB2V<DYZ]ZTM
M0T'Q5XP^$S:+KEU;:=KUUL=Y4BW1Q%)Q(F4#'G:J@C<1G/- &A;^/;.XM]4Q
MH>M)J&F/$DVFFU#7+"7_ %;*%8KM;#?,6 &TYQBJS?$[1FM+5K?2]5N=0N+F
MXM/[,BA0W,<D S*&!<+\HP>&.<C&:Q+[X?\ B;5I-3U:^URP&J7UQ9[H((Y4
MM9+:W\PB%\-O(8RLQYQPHY&<P#X6:E%X9N-)'_"/727.I7&H-;SV#K% 9%4+
MY)1@\;(0<,#D@]J .CU#XB:/IMT(9K747BCA@GO)UM]J:>DQQ'YP8AE)[@*2
MN,D 55M?&EQ-XEGTZY\J%1XD?1H=L9<RH+-9^3D;3DGGD8&,<YK";X1WB:A#
M<_:M)UB6>RL[6^NM;LC<S%X%VF5/F )<=0W< UM+X!OE\9'4EU2#[$->_MQ8
MO);S 3:?9VC)SC&0K X]10 ND_%;P[JD"73V^HZ=936$VIPWE]"(XIH(<>:5
MPQ/RY&<@9'(S6[H'C"S\07=Q9KI]_IM[#$EQ]FOXU1WA?.V0;688.",$@@CD
M"N/'PD:X\*:#X=OM75H-/T.]T:=XHB&D^T*B[UR>-NW.#G-;W@GP==>&[NZF
MOK70H9988X0VE6)A:0+DEG9B2<D_=' _&@"6V\?6>HZG<V>GZ9J;PHUQ#'J1
MM_\ 1)98<[T#@DC!##+* 2I )K)\'_%&W\0Z%I\U]I.HVNH3:*FK[1:DI=)M
M'F>0H)=L,< $ G(QD'-6M$\(^)M#:71[?6+%_#7G7<T<7V9C<MY[.^QFSMVJ
M\C'(&2 !67)\,=4'AW2=-L_$AL[K3_#+Z"MU#&RMYA\K]Z"&RH_=D8!S\W!X
MH UI?B=H]O8W=Q?:3K%G=6MS;6LEA+;*UP6N"!"0J,P(8G'!R.<BM"]\<6NG
MZE:6E]H>LVT4\EO UW);J((9IR!'&S;LD[F524#*"<$UR=G\*]0CO+J\DNM+
MLFGU'2[XV]C;.L:BTD#,,LV69\?>/XYJ;7/AMJVL>*[C4VU2PEMWU.RU&&2Z
MA>2XME@DC<P1G=M13Y9Y !^8YS0!OQ_$"PNKRYAT_1=7O((C<1Q7L5NIM[B6
M%27C5MV0?E8 L%4D$ FLG2?BM:WOAC2=5NO#NK)=ZA:O>M8P1QR/% A :8_/
MC9D@#G<>R\&KOAWPKXDT.X;28]6LSX9$]S.L0MV^U.)BS>6S$[0%9R<@9. /
M6N8_X5/J4=II#23:%J=WIEC+I:KJ%F\D+P%P\<FW=D2+R#_"0QZ4 =)J'Q+T
MF(7L&F+>7+P:6FJF\CM?,MXH71VC=CN!Y\LC;U_4B]9^.+&\UG^R+72]4O9(
M?*CN+NVM@T$4KPB54;YMRY5E^;&T;@"PK.F^'=P]OXDAAU"UACU?0[72(UBM
MO+2%HA,"X4' 4^:,*.F.M03_  ]U27Q=I>KK>:7;KI\ENWVVVMWBO9(HT"M;
MNP;;)&Q!^\#@,0!D T &@_$IM9L-'OKW3+C0X[W4+JU9+N-7$BPQS.65E<[0
M!$221U! '>KT/Q,T0Z->:U=:;K%EIT-K]NBN;BTPEU#N"AHR&/))7"MM;!!Q
MC)K,M_AK??9].TV\U*VET[3]1OKF/RXV662&YAGC*,<X# SGD<87IFK^E^%?
M&5KX9D\.WFM:/<6=OIXL;.-M/,BRXP \ZLV#\B[2J\?,3Z"@#I]#UIM:LY;A
MM*O],DCD\IX+^((^<!@05+*RD,.58C.1U!%<YXT^(%OX7CO[6UT^]U#5+739
MM29+>$.EO&H8*\OS [2RD87)X)Q@9JCX?\+^+/":6]MI;61M;W5UFN;.%7^S
M6%H(=K+#O;<I+J&P,C+$  <U8\6>"]>U?6]4U#0-4LK/^V-&.CWBW<#2;%!D
M*21[2.1YK@@\'CTH D7XE:7:P68U"UNW;[+:SW]U;1AK>Q,X&SS"6#<G^Z&P
M,$X!HNOBKH5OJ<UG_9.M3K'J#:3]HAM T378&1$IW9);L<;?4BL6;X4R)K8O
MK<:'>+<6]G#=/J=B9WB:!0A:+D#YE X;H0#6V/A[<@_\A2+_ )&C_A(/]6?N
M8QY77K[]/:@!Z_$K2YK&VDM=*U:XU.XNI[-=)2%/M2RP_P"M# N$ 48.=^#N
M&"<U!J'Q6\/VN@+JEC::AJ<?V&3494MX@#;0HQ1C+N8;<.K*0,D;6XXJFWP^
MUK3];;7]%U:T.IQZI>WL:7,+F%H;E4#1MM.=RE 01^5</XB\%ZEH-Y9V'V>Z
MU*.'2YR[)IUS/!J=S-<O/)"XMS\B%VZ2';ANOWJ /48?'5K->:QIXTG5I;G1
MHU-Z+:W\Y%D:-'$2$',C$.,8&.#G JM)\3-'AAW7&EZM%??VBFEG3C K7 G>
M,R(,*Y7#*OWMV!WQSBFW@O7-0\/>)&_M$:7J7B*XM;UHD+8MRD<(D@9D8%E;
MRV4E2#M;BN9OOA_XCT>\TZ[TA=.^UWGB6WO_ "[.S<6UHJ6DT9+C.2I. 6X.
M6H Z2\^*4;:EH$6F:+?W(O;F\L[NP\@?:X9X4#>7C=L!YR26VX(YYJU;_$[0
M[@C5&O6M])&CRZI*LUN1)&(Y3&^2#U!!7: <D<&H=%^'^IV?B33O$.I:M;S7
MR:A>ZC>)#"RQL\\21*D>3D!5C7DY)YK*C^#LLFCW&F7FN*8YM*N]/WQ0D,CS
M7;7"R#)_AW 8[XH Z.3XB6,.GM<7WA_7;*Y:YAM(;&XM52:XDE!,80[]AR V
M<N,8P<'BK+>*K@ZMX8W6,]II^N2SV;1WD)BG@N%C:1 1TP5BE'<'Y2"0:S]0
M\-^,M<\/W5EX@O/#VH>9+'BSEL&>U:-0=V[<VX,20P(^Z5&/6L^R\)ZMI\O@
M;0[B:6^ATJ_N=5N+H!S%"HBE2*!6<EL W V@DG;&: /5J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF_[_ .F__)='_"6Z]_T3'Q-_W_TW_P"2Z .OHKD/^$MU[_HF/B;_ +_Z;_\
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M-M9;N98EW.4C0L=H[G KS;3?C1#)X'U+QAX@\)ZAH^E6EG%?07"31W4=VDA
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M:2>2.* /I"BLZU:\-G";Z.)+LHOFK"Q9 ^/F"D@$C.<$@5HT %%%% !1110
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MJE[8VNHV$]A>0B:VG0QR1MT93U%6Z* .+_X5;X!_Z%FV_P"^G_\ BJ/^%6^
M?^A9MO\ OI__ (JNTHH XO\ X5;X!_Z%FV_[Z?\ ^*H_X5;X!_Z%FV_[Z?\
M^*KM** .+_X5;X!_Z%FV_P"^G_\ BJ/^%6^ ?^A9MO\ OI__ (JNTHH XO\
MX5;X!_Z%FV_[Z?\ ^*H_X5;X!_Z%FV_[Z?\ ^*KM** .+_X5;X!_Z%FV_P"^
MG_\ BJ/^%6^ ?^A9MO\ OI__ (JNTHH XO\ X5;X!_Z%FV_[Z?\ ^*H_X5;X
M!_Z%FV_[Z?\ ^*KM** .+_X5;X!_Z%FV_P"^G_\ BJ/^%6^ ?^A9MO\ OI__
M (JNTHH XO\ X5;X!_Z%FV_[Z?\ ^*H_X5;X!_Z%FV_[Z?\ ^*KM** .+_X5
M;X!_Z%FV_P"^G_\ BJ/^%6^ ?^A9MO\ OI__ (JNTHH XO\ X5;X!_Z%FV_[
MZ?\ ^*H_X5;X!_Z%FV_[Z?\ ^*KM** .+_X5;X!_Z%FV_P"^G_\ BJ/^%6^
M?^A9MO\ OI__ (JNTHH XO\ X5;X!_Z%FV_[Z?\ ^*H_X5;X!_Z%FV_[Z?\
M^*KM** .+_X5;X!_Z%FV_P"^G_\ BJ/^%6^ ?^A9MO\ OI__ (JNTHH XO\
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MDMX)+?3M/FMYI=1C>&_DE=_.8EPSW .-F$/R\$=17T)0!Q_]F_$K_H</#O\
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M=A10!Q_]F_$K_H</#O\ X3TW_P FT?V;\2O^AP\._P#A/3?_ ";7844 <?\
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M6^CLH([^>*>[" 2RPQ&)';N50LQ4>VXX]36A10 4444 %%%% !1110 4444
M%%%% !1110 QE5L;E!P<C(Z&N=UKPO9ZY<6=Y)<75E>63,T-S;,H==RE6!#*
MRL"#W!QVQ72T4 8>C^']+T/2[+2[&T46]DNV$O\ .ZY.2=QYR2236Y110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %9.L:3;ZUHM[I-U(ZV]Y"]O(8
MR P5@0<$@\\UK5C^(-3&B>&M3UC8'-E;23A3_$54D#\30!3O/"^F7NFZ39SM
M,L>E7%O=0LC ,[P_<WG'(]>GX5@CX8Z3_8ESH9U;5CI4D)A@L_-C"6B[PXV8
MCRQ!4 >87P..YSP7BCQYXHT>_EMY/$UQ:75MX<LM0BBBTQ9XKF[EDG#"5@O[
MM/D09W* ,G-=W>^/FTOQ#I>CZCI\!:ZEM;61HKV-I%EF'!$7WM@;C<<9ZC.*
M +UC\/=+LM174I-2U&\O/[175&EG>,;YA;K;@$(B@+L4< #GVXK:T'1;7P_I
M2:78R2/ LLLH,K MF21I&Z =V./:N+MOBH6M4U"^\-W%KI]Q:WEQ;2K.DCRF
MV)WJ5'W<@$@GTYQ55OBQ);S3PWEA913-=Q6=JHOU,;LUOY[,\N-H 3' R<^Q
M% 'K5%<[X8URW\3>';'7+>&2VCNT+>5)]Y&!*L,]\$'D<'K714 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !117GG]J>)M9;Q0VBZA#91:?J$=C$\MO
MYI2..)'GD51]YR9"J@G'R ]SD L-\/-/FU87-]JNIW]A'/-<Q:7<RH]M%)*&
M#D?)YA'SMA6<J-QP!QB.S^'=G9_,OB77998;,V%E,\T7F6$)96*Q$1C).Q1N
M?>V!C/6N<L_$WC#5? 4FLPZLMM%87=U%<3PZ2TU[*B-B(?9L_(YSEAUQ@@#=
MQT^A^)#XB\(Z5:KX@TZQ\47^G17;I;%9_++*"S+&3RN<B@">;P3:77B!-3O-
M:U:ZM8[H7R:;-,C6ZS@8#_<\S /S!-^P'D+7:5X?<>-/&&FV]VIUI=2M[O64
MT>POH],RX**YN'6-&P_SKY:Y(&58GBMW1O%^J2#09+G5%ODGU:?2+M3:&VE2
M3RV>,2(<['4+S@[2"".M 'J=%%% !1110 445R/C35+S3='MET^017U_?6UA
M#(5#>69955GP>#M3>P![@4 6]>T,:U;V_EZI?:7=6LWG075BZAT;:5((=61E
M(8@AE(Z'J :YM?AKIMND3:?KFLZ;>>3+;W-Y!)$TMZDDAD?S-\;+G>S$% I&
M3C XJKJFO>*]$^(6D6ESJ5N]CJE\8([1;)A$EOL;!:X)XG+*,)T.< =Z@\'^
M,M06^E7QQJ5QILLEO-=1V]_IRVD(C20!F27<=VT,F=V#\P- '0S> ]+FT7^Q
MUU'4;>UA^RFR6.9?^)>]O@QR1;E/S9 +;MP;N,$BM/P[H-OX:TZ2SMYKB[DG
MGDNKBZN64RW$KG+.VT!<^P     KSSQA\1M8LO$<H\/ZE!)80VEK<VYAM?M,
M%P99&5O/G!Q H4 @^A+<@8JW#XO\22:Y!JCWMNVBW/B.7P^M@MN-Z(N]%F$F
M<EO,3.,8VGU&: /7**Y;P7JUYK'A]I-0=9+VTN[BQG=5VAWBE9"P';.VNIH
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MW]6_\$E]_P#&:[*B@#C?^%F>$_[^K?\ @DOO_C-'_"S/"?\ ?U;_ ,$E]_\
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M1_PK'X:_]$]\,_\ @IM__B* .MW+_>%&Y?[PKDO^%8_#7_HGOAG_ ,%-O_\
M$4?\*Q^&O_1/?#/_ (*;?_XB@#K=R_WA1N7^\*Y+_A6/PU_Z)[X9_P#!3;__
M !%'_"L?AK_T3WPS_P""FW_^(H ZW<O]X4;E_O"N2_X5C\-?^B>^&?\ P4V_
M_P 11_PK'X:_]$]\,_\ @IM__B* .MW+_>%&Y?[PKDO^%8_#7_HGOAG_ ,%-
MO_\ $4?\*Q^&O_1/?#/_ (*;?_XB@#K=R_WA1N7^\*Y+_A6/PU_Z)[X9_P#!
M3;__ !%'_"L?AK_T3WPS_P""FW_^(H ZW<O]X4;E_O"N2_X5C\-?^B>^&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* -Q !XY[T <!\+%C/AK59K%572I]8O)=.\M<1FW,GRE!TV$[B,<8/%>A4<
M>@I 00".1ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4450O'ODL9
MI-/MXI[M4)BBFE,2.W8%PK%1[[3]* +]%<=_:GQ*_P"A-T#_ ,*"7_Y#H_M3
MXE?]";H'_A02_P#R'0!V-%<=_:GQ*_Z$W0/_  H)?_D.C^U/B5_T)N@?^%!+
M_P#(= '8T5QW]J?$K_H3= _\*"7_ .0Z/[4^)7_0FZ!_X4$O_P AT =C17'?
MVI\2O^A-T#_PH)?_ )#H_M3XE?\ 0FZ!_P"%!+_\AT =C17'?VI\2O\ H3=
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MS8@8MN)3_0OE)//'?FM#SO'PLY+-? OAG[/+OWPG7)-C[B2V1]CP<DDGUR:
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MJUA)YEI>P)<0OC&Y'4,IQ]"*OUGZ7IUKI&CV6DV$?EVEE"EO"F<[410JC/T
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M*_\  */_ .)H_P"$3\*_]"SI7_@%'_\ $UMT4 8G_")^%?\ H6=*_P# */\
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M_7]8\5>'-4L9KC2;>YU+4)?*F$DWFR#Y1$[G: 515&2JH,^I /1_[/\ A_\
MVU_8O]FZ!_:6W=]D\B'S<8S]W&>G/TK4_P"$3\*_]"SI7_@%'_\ $UXQJEC<
M#QV=%T6ZBFNY?$T6J,DNFRK>1*=K2-YV=GD[ 0&QT(3'&:^@J ,3_A$_"O\
MT+.E?^ 4?_Q-'_")^%?^A9TK_P  H_\ XFMNB@#$_P"$3\*_]"SI7_@%'_\
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M4"+?C>?,P>>B$XH [#_A%-?_ .BG>)O_  'TW_Y#H_X137_^BG>)O_ ?3?\
MY#KF? _B_P 2>+]=M!<36=K8)HMM?3PQP%FGEDEN(R4<M\J'R58<$\]:71]<
MN]%\*?$G7A&U[+I>JZA/%$[$@B.)&"^PX[4 =+_PBFO_ /13O$W_ (#Z;_\
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M-O;&'R&D.&C^\VX=#DX->FT <A_PBFO_ /13O$W_ (#Z;_\ (='_  BFO_\
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MWMC>7;202VVG:G;W M/LC;7OD0A5WL3&01@M@]>N> #TW_A%-?\ ^BG>)O\
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M<R,@/(R)<$'H1[UQUWX\\8:MH>MZI!<6UA9GP7/JL<4)/FP7 \U0ZOCJ"@H
M]ZHK@O"'B+7-0UG4-#URWM$N+.UMKJ.6U=F#I*K<-N ^8%>HX.:[V@ HHHH
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MU0,O4QR$DG@ <<T 7;KP-X7O);B62QGBEGNC>-);WD\#K,R[&=&1P4W+PVW
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M_/>/_OH4?:+?_GO'_P!]"N9_X5K\.?\ HG_AO_P50?\ Q%'_  K7X<_]$_\
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M^;(XQWZT =E'H_F>.AXDU#4H9DMK(6ME;KQY+,<S2$D\EL(!Z 'UKJ/M%O\
M\]X_^^A7&V/@#X;WUA#>)\.=#@$J[O+N-&ACD7V92F0?8U<_X5K\.?\ HG_A
MO_P50?\ Q% '3?:+?_GO'_WT*/M%O_SWC_[Z%<S_ ,*U^'/_ $3_ ,-_^"J#
M_P"(H_X5K\.?^B?^&_\ P50?_$4 =-]HM_\ GO'_ -]"C[1;_P#/>/\ [Z%<
MS_PK7X<_]$_\-_\ @J@_^(H_X5K\.?\ HG_AO_P50?\ Q% '3?:+?_GO'_WT
M*/M%O_SWC_[Z%<S_ ,*U^'/_ $3_ ,-_^"J#_P"(H_X5K\.?^B?^&_\ P50?
M_$4 3^*H+[5O"M]IFCWEE#=7<30>9=[FC56&&X4@YP>*X2^^&-QJWA&&SOO%
MTUCK$.C'15DT]E%LT6,9*2!F&["[L,,[0.PK;UKP?\-=%MHIYOACIEZ)&VA;
M#P_'<,O'4A4.![UA>7\%8_ ]SXRO/!.A6>E6TK0R&XT.*.3S%?84"%,D[N!C
MK0!KZUX5UC4- ATB37K*ZM[&6TEMDO8]XN3$#YB7." ZL<$  8('6MGP3H;>
M&M*NH;R\M&EN[N2Z\BT7R[>VW8_=Q*3PO&?<DFLO5/"/PGT70I=<U3P=X9L]
M/B02--+I<  !Q@?<Y))  ')) %2Z-X+^%>O:'9ZQIO@3P_)9WD2S0L^CPJ2I
MY&04R/H: .[^T6__ #WC_P"^A1]HM_\ GO'_ -]"N9_X5K\.?^B?^&__  50
M?_$4?\*U^'/_ $3_ ,-_^"J#_P"(H Z;[1;_ //>/_OH5("& 92"#W%<K_PK
M7X<_]$_\-_\ @J@_^(K<L[2UT^RAL[&VBM;:)!''#"@1(U' 55'  ]!0!H44
M44 %%%% !1110 4444 %%%% !1110!PGQ.TG4=>^'=]INF64UY=/+ X@@D6.
M1U69&;:S,H!P#C)%<+;>&O%5LEZUOX9NO[(O=9ANC:ZD]M>W\8$#!Y?FD,9R
MXB !=BJAB!T%>ZT4 ?/T?@GQ-9^'O#4<?A6:?6;.U-MB5K6>U5/M)?RY59@4
MP-K!XLD=,<"KUKX%UYO$.I?:M/NGN7NM3N(M14VRP2)<+((PS F9N'1=A  V
MY!PJU[G10!X*O@7Q%J+VG]H>&R+?9H$<T%Q)"P(M9+@SY <@@!T/N&XYR FI
M> -=AE39H<L^DPZEJK+IUFEJY$=PP,<BI*P0 C>.H8;^G6O>Z* /,=<T&X_X
M0OPSIDWAF^UV/3TC28V]\J:A:LL6U9(Y"T:LV>&^89!/!Z5A6OAOQM'<Z/KE
M]H?]K:M#8:G:P27LD#36^]RUH+AP1D[ $9H]W+'L2:]KHH ^;-0T77M&L9[R
MZT'["MY+I-O;6UQ':PQ33Q22,R-'$YCV@8QO89XYR *2+PO>:]9,UCI.H:C8
M1P7^F7%M EF#;W<EQYSF,N^Q(L285XR67;TR,5]%7-K;7EL]K>6\5S#(,-%*
M@=6'N#P:+>WM[6V2WM(([>&,82.)0JJ/0 <"@!EI;M!900LS.T<:J6<[B2!C
M)/<U=HHH **** "BBB@ HHHH *SM5TVUUC2+K2[Y6:WN8S&X4X.#Z'UK1J&2
M1(XVDD8(BC+,QP /6@#Q6;P5XLT^YCU#2UU%[J>><)BZC#VY,RO'),=P#*V;
MAW5<\R(,$*,;GQ"TG5[S7'O-)\-ZC-J L/*T_6-'O8X)H9MS'RYUD=0T6=C#
MA_X^!W]$AOK.XA@FANH98[C_ %+I(&$G&?E(Z\ ]/2H-0U[1=)N+>#5=8L["
M6Y.V%+B=8S(?]D$\]10!Y7>>&?%%I=>(YE\*6NHWFK?V=-/=QQ6[K*$6-;A5
M1W7+AE+@/A#P<YXKC]6T/5K&"TT;4-+$?VJ36KG[/<M;9CM)63]XBEA$LGSY
M #9&3QC)KZ8#*Q(5@2.N.U4KS3=/U)4CU&QM[Q(VWJL\2R!6]1D<&@#QG0O"
M]_J?BJTU]+#5;G3KZ\L]4L+\_9T,-NMK&@25F/FA@5?**"K;\YY:MWQIX4\0
M:KXLU6^T_3S-;SPZ0L;^:B[C!?-++P2#\J$'WZ#)XKUCH..!6;)JFGPWZ6<V
MH6\=R^T+"TJAVW9VX&<\[6QZX/I0!SO@72-0TFPUJ'4;<P/<:U?W47S*VZ*2
M=F1N"<9!!P>?6NUJBEU:R7TMJEQ&\\*JTD2L"R!L[21U&<''T-7J "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#AOB1H.H>(O![V>F^8]S!=07:PQ2")
MY1'(&**YX5B <$]\=.M<:/#NM3037&I>$]=O]$345FL],DU91J%JOD;7<.)L
M%6D/W#+D#)[[:]BFFCMX7FFD6*- 69G. !ZD]JI_V[HO]GIJ7]KV7V)VVK<>
M>OEL?0-G&: ,?P+9ZUI_@BQL]>:7[<C3'9/-YTD41E<PQN^3O98RBDY.2IY/
M6NMJM;W$%U;I<6TR30R#<DD;!E8>H(ZU9H **** "BBB@ HHHH YOQ,^N+X<
MOU\.VPGU:51%;[F"K&SD+YC$D<("6(')"X&37G_C+X<^)9O#$.E>%IM.N[#3
MM(FM;:QO8W\Q[IU96GW!U7S""0"W +N>]>L7=Y:6%H]U?745K GWI9G"*OU)
MXJK<:UH]K%!/=:M9PQ7 S"\DZJL@]5)//4=* ,);KQ!#X=NK.\\.S7-U:6<2
MH;-XMMW(R881B20;=A_OD9[$TWX<V^J6/PYT?3=7T:YTN]LH%@D@N'B8DJ/O
M QNXP?KGVKJ)[RUMK-KJXN8H;95W--(X5 /7)XQ3[6YM[RV2ZM9X[B"0;DDC
M8,K#U!'6@"U1110 4444 %%%% !1110 4444 %%%% !1110 445EZFNK2:=*
MNB7%K!>DCRY+N%I8EY&<JK*3QG^(<T :E%<=]E^*'_0>\+?^"FX_^2:/LOQ0
M_P"@]X6_\%-Q_P#)- '8T5QWV7XH?]![PM_X*;C_ .2:/LOQ0_Z#WA;_ ,%-
MQ_\ )- '8T5QWV7XH?\ 0>\+?^"FX_\ DFC[+\4/^@]X6_\ !3<?_)- '8T5
MQWV7XH?]![PM_P""FX_^2:/LOQ0_Z#WA;_P4W'_R30!V-%<=]E^*'_0>\+?^
M"FX_^2:/LOQ0_P"@]X6_\%-Q_P#)- '8T5QWV7XH?]![PM_X*;C_ .2:/LOQ
M0_Z#WA;_ ,%-Q_\ )- '8T5QWV7XH?\ 0>\+?^"FX_\ DFC[+\4/^@]X6_\
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M$*1LW<JI)('L2?K0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^Z.>OM0!=HJJ]U;1W*6[W$2S2#*QLX#,/8=333>6JSK US&)7)"H7&YB.H
MH N45D:;KVDZS<7D>EZA!=O93-;W"Q."8Y%QE3^=/DU;2X;U+.;4;9+EVVK$
M95WDXSC&<]!F@#4HJC)?V,49FEO((XPVPNTB@!O3.>OM5GS(_,$>Y=Y&X+GD
MCUH EHJE)?64,/FRW44<>-V]G &,XSGZT37EK;K&UQ<Q1"4A4+N%W$] ,]:
M+M%022QPPM+,ZQHHRS.< #W-8^G>)-*U.\U>"WFQ_9,J17$KX$>6C60$-G!&
MUQS0!OT54^V6IMUN/M$7DL"RR;QM(]0:1+RUD>...YB=Y5WHJN"77U'J/>@"
MY15/[5:M>-:K<1&X5=S1!QO ]2.N*KRZMI4-['92ZC;I=2,56$RKO)"EB,9S
MT!- &I15"34+&&,/+?01H6V!FD4 MZ=>OM2S7EK;_P#'Q=10]/\ 6.%Z].OK
M@T 7J*Y^3Q+I,'BB3P[<3>3=QV:7K/)A8_+:1HP-Q/7<IXJVM^K:O/I_V>9?
M)A2;SV7$3!BPP&]1MR?J* -6BJ27UG+:-=QW<+VZYW2K("@QUYZ5+#-%<0K-
M!*DL;C*NC!@P]B* +%%4X[VSF$OEW<,GDG$FV0'RS[^GXTZ.YMYFD6&>.1HC
MAPC@E3[^E %JBN>@\3:3=>)O^$>MKCSKPV9O=T>&C\L2>6?F!Z[NU.TOQ)I.
MK7FH6MO+LGL;Q[&1)<*7D5$<[1GYAAUYH WZ*J&[M5NUM&N8A<$;A$7&\CUQ
MUH6ZM7NGMEN(FG0;FB#@LH]2.HH MT5BZGKVF:7H>IZO-<++;Z7!)<7*PD.Z
M*BEF& >N >*+75K>[NQ$L,\<9MH[E9Y$VQL') 4'/WO4>XH VJ*IQW5K-&\L
M5Q%)'&2'97!"D=<GMBI(+B"ZA6:VF2>-NCQL&4_B* +%%9\VHV<(N6-PC/;1
MF26-&!=5 SR.M5M#UW3_ !!HUCJEA,&BO+6*[2-B!(J2('7<O8X(H V:*IQW
MMG)YPCNX6,)Q)MD!\L_[7I^--DU"PC56EO+=%+>6"TB@%O[O7K[4 7J*J375
MO:F-)[B*)I6VQAW"ESZ#/4U4M==T>]UB]T>UU""74+';]HMU<;XMPR,CZ4 :
MU%4HKRTG@,T-U#+$&VETD!4'TR.]5(]4AEU&XM%1PD$*S-<D#R6!+# ;/4;3
MGTR* -BBL2^\1Z#IT%E/>ZK:PQWLRV]NYE&V60]%![U-;ZI#-]N:2.2VBM)3
M$TLX"(_RAMRG/*_-C/J#0!JT556Z@:!;A9D,3 $2!AM(/3FG&>%2X:5 8QN;
M+#Y1ZGTH L454^U6INA:BYC,Y7>(MXW%?7'7%,-Y:JDC_:(0L:[G)<84=,GT
M'!_*@"]14$4L<\2S0R+)&XRKJ<@CV-3T %%%% !1110 4444 %9^K63:EH=_
MIRR>4UU;R0A_[I92,_K6A10!\X^%=4^(7AGX;Z1\,8?A3=7FM:>Z61O;N)'T
MF2)9,^>9 P)^7G&,[JYWQEX'\3W7B?QE"W@W5-3\4ZGJ]O<>'_$<'^HL+8;,
M+YF[]T$VOE<?-D=:^L** /E7QA\,M:U9_BYK,GAB[O=:,]C)H5RJMO9EC7S'
M@YX.1R:LZ]X3U1OB+XFNO$GPYUGQ;>:D]@VA7]K<&!+)$0!U,X.;<JV2Q .[
M'>OJ&B@#Y<\7>$?&3-\5;&S\-:E</J&I:?K5E-  T=U'$8_,C1LY,@P?E(&<
M&G:OHGB3QCJ'Q-U2\\%^*-.T_5].TZ.UA54CNI/+/S[5+%21C)0G)''&:^H:
M* /D[2/"'C;_ (1%K%?#-S';Q^,-+NX9DL6L9;F!&!FE>UWE8@N!DK@-R:-0
M\#^+'\7ZK;KX0U2;QC<>+AJ-GXJ4#[/#IV]6">;N^4! RF+'?'-?6-% 'RAK
MWPUURX/C;Q!%X7O9?$ \90W6EW*JWFBU\Q"SQ<\)C=G'7'M7NWA6RLK?QAXP
MGMO#.H:5/<7<33WMS(6BU%A'@21#<=H'0X YKN:* /,ET?5AXD^*$_\ 9\WE
M:E:6Z6;[>+AA;.I"^N&(%<9'X!UK3]%T:W\+Z/)I.I7'@NZLKB=!Y>V],47E
M"1L_?#[\$].:^@** /&/ACHMQ8^)WO(['5;&W72H[:=+G34L8O,#9"X',KJ-
MW[P9&#U.:R-=\&S%O'NFVWA6X,VK:SIMXD]O;D)<6WVFV,H$@[C;(S+UQDU[
M]10!\]>,O!M\GBG7((]+U%M-N=/M[?1TTO34N!#M4AD60_\ 'LV\AMW YSGB
MHO%FB^)+S7-6:W\.WW]JIJ%A);W,-B9FGCC:+=,;IFVIC#YCC"]#P<DU]%44
M > ZMX/G6Q^(&D6OA6<76IZQ:WD<T%N0ES;&: L!(.XVR$KU')J37OAO#N^)
M9T[POQ)8V[:.(X\#SQ"=S0CL^X+DC!R!7O5% 'SKKGA?Q%<>*]9>^M=8FO;Z
M\M)]/N+/3TEVQJD8Q]I;_4;&5]P.,\D9W5IZCX(O9++Q-K$>@S'76\5175G.
MJ$S>0LL/SH<\+MWYQ[U[O10!YI\/]%A\.^)/&D$N@/ITD^J2WL=VMOMBGMW"
ME=L@X)!W97J*\C\-1R7%C;7%Y8RVUU=Z?J=II5REFS2:M),CNOF3[B&.U,C
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M()D./KQ5K6/!^L#4?B+#I/A^:SU?6](MS87T:[P2L(2:(S]G)&.<;NM>]44
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M^L6.D3Q6E[<K<JLN]@I/EQD?/M5U+9*YYQFM7QCX?FUGP<UCI(BBO;.2"\L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_s3img18.jpg
<TEXT>
begin 644 cvm_s3img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &S M<# 2(  A$! Q$!_\0
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M[FVCN(K>2XC2:7/EHS ,V.N!WQ7E'B[Q]K6EW-S-HFH0WEK8;8I0NG22(\O
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M'H<T*ZL"58,!Z'->#^%YM8\/V=UX=M?-2[UFU35VNGRRVJ."9GSZCC ]:W?
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MRP!&#Q2C&[U94I61[#17,^,=6U+1/#4]_I-B;NY5E7 0N(U)P9"HY8*.<"N
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M.Y40C!P !SCN>:ZZBAU).^H*G%'.^&?#4?A?3S86^J7U[;C B6[D#^2HZ*N
M.*YB/P/?:AXCUO5M2UC4=--[.$6*QN@JRP*N%W<<$\],&O2N*2I4I*[ZL;@F
MDNQQM_X%TBZM=-BL[B[T>33 R6\]C+L=4;[RDG.0>^>]9&I_#WSKS0]/T^:Y
MM-.M)9;RXO(KC%P]P5PK$G)8\DUZ5S2U2G)=0<(OH<7#X#TA=(U&PO)KN_EU
M2/RKJ[N9=TSKV&[L!V J'2_A_8Z7J5OJ<VL:KJ%S;0/;PM=W&\1HPQP,  @=
MZ[JBCFEW#DCV.(D^'FFBTTJ*TU34;&73%=([BWF"R2*YRP8XYR:9_P *[TD>
M&7T-+[4%!O/MPN_/S.LV<AMQ'./>NYHI<TNX<D>QRD'A&S2\2]N[RZU"<6;6
M+-<N&WHQRQ.!U/2J>E_#_3=+N;>?^TM0U!;+/V*"[GWQVG;Y!CJ!P"<XKN**
M.:7<.2/8Y!?!>ECPR/#OF7!M//\ /=BPWR-YF\ACCH3^E;^J:>FI:+>::QVK
M<0M%GTR,5?I:'*3U8^5(XJQ\,S:CX)TK1?$"O!)9-$76&0$2>4WRY/H< D5M
M_P!AVK>)U\0.TANDMS:HI;Y$4MDD#U.!6U10Y,%%(YV7P?X7GG>>;P_I\DLC
M%F=K=26)[GBJNO>#K77-%BT:'4;S2;) 5:+3V6-74_PD8/%=924*4EU#ECV.
M8A\,R0>&%T&+7M3!4!5O?,7SU Z '&,8XZ4SPGX2B\)VDUK;ZMJ%[#(Q<)=R
M!@A))8C '4DFNKI*.:337<.57N8D^BVK>(D\0'S'N8;9K>-,C: 2"<>YP!6=
MHNDZBVMW/B+7E6.]F7R+>V1MZVL(.<9[LQY)'L*ZVBCF=@Y5>YS]UX=L[W78
M]:DEF^T16LEI&%;Y45R-S#_:XZU47P9I?]AZ5HIDG-IILJ31@L,R,I)&_CGD
MYKJZ*5WW#E78H7]E!J6G7-C=9,%Q&T;@'!P1@\US=CX%L[/3K"PFU;4+Z&PN
M$N(!<RAMNP85.GW179TE"<DK)@XI[G+W'A/2K[4=4O;U7N#J5JMG+&[?*L8R
M<+Z9)S^50Z'X.CT.Z2;^W-7OXHT\N&WN[G?'&O3I@9X]<UU]%/FE:UPY8WO8
MP]1T2UU/5-+O[B23=ILK311@_*S%2N2.^,\4_6-#M=<CM([QG$=M<QW05#@.
MR'(#>HS6S12YGIY#L<OJ?A'2]6O[^[O&E9KRR^PLH; 2/.25]#G'Y5G:;\/[
M&QU.WU*;6=6OKFVMWMXFNKC<(U88RH  ! [BNXI:I3DE:Y/)%N]CBK'P'8V]
M['=ZAJFI:NT(9;=+^;S%@##!VC YQQDYI-)\"6VBWL#VNN:N]G;-N@T^2ZS!
M'Z#&,D#L":[6EI<TNX<D>QGZC8IJ.G36,DTT*S+M\R!RCK[@CH:YS2_!%G8Z
MK#J5]JNI:S=VX(MWOYMX@SP2H  S[]:[.FT*32M<;BF[LQ-<T1M6M8H8]6O]
M->-MRS64NQOH<@@CZU@S?#G29M(%DE]J$-T+L7QU!)O](:<#&\L1@\<8QBNZ
MI::G);,3A%[HXG4/ 5I?7]GJ']N:M;7MO;_99)X+C:]Q'G.'./7N,5#_ ,*]
MTC_A'--TFUOK^U?39FGMKR*;$ZNQ.XEB.<Y(.17>4E'-+N')'L</'X5D\-Z3
MK$VA_:-7U6_PQ;4+C<6;&T98_P (ZXJ_X+\+V?A/PO;Z3:X9Q\\\N.99#RQ^
MG8>V*ZJC-#FVK,%!)W04445)84444 %%%% !1110 4444 %%%% !1110 444
M4 5)KZSMY!'<7<,+D9 =PIQ^--_M73?^@A;?]_5_QK+2VM[CQA?^?;QS8MHL
M;T#8Y;UK6_LW3_\ GQM_^_2_X4 -_M73?^@A;?\ ?U?\:/[5TW_H(6W_ ']7
M_&G?V;I__/C;_P#?I?\ "C^S=/\ ^?&W_P"_2_X4 -_M33?^@A;?]_E_QH_M
M33?^@A;?]_E_QIW]FZ?_ ,^-O_WZ7_"C^S=/_P"?&W_[]+_A0 W^U--_Z"%M
M_P!_E_QH_M73?^@A;?\ ?U?\:=_9NG_\^-O_ -^E_P */[-T_P#Y\;?_ +]+
M_A0 W^U--_Z"%M_W^7_&C^U--_Z"%M_W^7_&G?V;I_\ SXV__?I?\*/[-T__
M )\;?_OTO^% #?[4TW_H(6W_ '^7_&C^U--_Z"%M_P!_E_QIW]FZ?_SXV_\
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M_P#OTO\ A0 W^U--_P"@A;?]_E_QH_M33?\ H(6W_?Y?\:=_9NG_ //C;_\
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MS=/_ .?&W_[]+_A0 W^U--_Z"%M_W^7_ !H_M33?^@A;?]_E_P :=_9NG_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G5/\
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MH **** "@]**#TH YG1X[N30(UL[E8&\Z3+-'OXWGC&:O?9=<_Z"D7_@/_\
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M'?'&3,AD8(I>%U!)Z#)%:M2TUN@%HHHI@%%%% !1110 4444 %%%% !1110
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MGW%DD"EOIGK3UFCE+B.5'*-M8*P.T^A]#7)^./#/_"32:19C3H)8UN1)/=R
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MBBBJ+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!M<_I/_(SZ[_UUC_\
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M//Y4 =A;?\CGJ'_7M%_-JVZYO2X;B#Q9J*W-XUTQMXL,R*N.6]*Z2@ HHHH
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M6^SQ?\\4_P"^11Y$7_/%/^^16OO=T<MZ?9_>O\C)_P"$JT'_ *"4?Z_X4?\
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M_OD4>1%_SQ3_ +Y%'O=T%Z?9_>O\C)_X2K0?^@E'^O\ A1_PE6@_]!*/]?\
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M4 %8FJ?\C!H?_763_P!%FMNL35/^1@T/_KK)_P"BS0!MT444 %%%% !1110
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M?\C!H?\ UUD_]%F@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#SGX@:6^JW^EVL>AWUT[DC^T+<Y%E@@Y"[A\Q./FYP,U7\ Z'KFFWE^
MUU;2V+-;B*:29MXNKG>Q,P&>1M(&>/3M7IU% '-:3'>1^+-26]NDN'^SQ898
M]F!EJZ6L2V_Y'/4/^O:+^;5MT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #&KFM'_Y'#7_]Z'_T772M7-:.#_PE^OMV+P_^@5G+=>IO2^&7I^J.
MHHHHK0P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K$U3_D8-#_ZZR?^BS6W6)JG_(P:'_UUD_\ 19H VZ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XSQKI>I7USX?N
MM,FO ]KJ,;21PR$1E.<M(.X%8/@/3M?L[O4FN8+FV?R0MRUX699[O>Q,BY/*
M[2.1@=/2@#MK;_D<]0_Z]HOYM6W7)6_]H1Z[K+7LT+3"R0JT*E0/O>I-3:;X
M?T^;2;.:62[:22%&9C=2<DJ"3UH Z>BL3_A&=-];O_P*D_\ BJ/^$9TWUN__
M  *D_P#BJ -NBL3_ (1G3?6[_P# J3_XJC_A&=-];O\ \"I/_BJ -NBL3_A&
M=-];O_P*D_\ BJYV-M.D\?S>$SIM^ICLQ>?:_MS;"I;;C&[.<T =[17(RP^$
MX;U[.;5#'<H"S1M?." !D_Q>G-02+X=DT*^U72;B;4ULXV=HX;Y\DJ,[<[N#
M]: .UHKR[P[K_AW7)[>"XM;_ $U[G31JL9DOF=1 2 =Q#?*02.#6M)>> XK6
M*ZD\11I#-NV.VHN VW[V/F[=Z .[HKS_ ,/W.@Z]>:E:^5=VLEG>O9QAKYV\
M_:BMO7#="&K$O?%&@Z;KNL:??:3J<<&DW-O;3W"WS-DS8V,J[LD<\]Q0!ZW1
M7*7&G^&[/4+73[J_EBN[O=Y$3WD@:7 R=HSS@5D:IJ7A"RTF_O+*^?4KFTMG
MNA:0Z@P>14&3C+4 >A45P6CWO@W5],L+M-4:*2\C#B!K]]R-L#LA^;J >:UK
M'2_#NI6YN-/O)KJ(,4+Q7DC ,.H^]UH Z>BL3_A&=-];O_P*D_\ BJ/^$9TW
MUN__  *D_P#BJ -NBL3_ (1G3?6[_P# J3_XJC_A&=-];O\ \"I/_BJ -NBL
M3_A&=-];O_P*D_\ BJJ6UC'I_B:"&U>?RY+9V=9)F<$AA@\DT =-1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 -;I7-Z/_R-FO?]=(O_ $6*Z1NE
M<WH__(V:]_UTB_\ 18J.J-Z?PR]/U1TU%%%68!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:I_R,&A_P#7
M63_T6:VZQ-4_Y&#0_P#KK)_Z+- &W1110 4444 %%%% !1110 4444 %%%%
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M93QN*@?)R#UXXJ+QQKVI6/C.46^O7,,5I'$T=G:R+')N)Y/ENN+@-TP&!'-
M&YJGPVT^YLX_[+U.\M+Z*^6^BNYIFG:-OXE7<>%921@5BZM\+]<U+Q+<ZH-<
MLA L%S;6D)MB"D<T03#$'D@C.>^:Q+SQ-KEOHQUS3_$UW>>*VNGB;P\R@Q ;
MB/+\K;N&%PV[/-=CX1U"!M6A\GQM=ZRUQ9M/=6TZ!EB<$?,"H'E8Y&P]?PH
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MT"__ +4?0]0$4T7GZ>S;;@YDZKU/?ZT =?1110 4444 %%%% !1110 4444
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MQEVC71E+MO8JK#<WJ>>34W_"'>%O^@#9?]^A6?=>"]!DU2PFAT2R6&)G,HV
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M9NE^!]!MX9UO-%LG9IW=/DSA">!0!U7G0_\ /9/^^A1YT/\ SV3_ +Z%8_\
MPAWA;_H V7_?H5GZEX'T&XA@6ST6R1EG1V^3&5!Y% '4>=#_ ,]D_P"^A1YT
M/_/9/^^A6/\ \(=X6_Z -E_WZ%'_  AWA;_H V7_ 'Z% &SY\/\ SV3_ +Z%
M)YT/_/9/^^A7+Q^"=!76[BX?1+(VKPHJ+Y8X8$YX_$5H?\(=X6_Z -E_WZ%
M&QYT/_/9/^^A1YT/_/9/^^A6*W@[POM.-!LLX_YY"J.F^"_#\&FPPWFBV3S+
MG<?+!SR2.?I0!U'G0_\ /9/^^A2^?#_SV3_OH5C?\(=X6_Z -E_WZ%9]SX+\
M/R7=E)#H=DL<4A:4>6!D;2/QYH ZCSH?^>R?]]"CSH?^>R?]]"L?_A#O"W_0
M!LO^_0H_X0[PM_T ;+_OT* -CSH?^>R?]]"CSH?^>R?]]"N7M?!7A^.^O9)M
M#LFBD=3$/+!P N#].:T/^$.\+?\ 0!LO^_0H V/.A_Y[)_WT*/.A_P">R?\
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M:U+QJEO<7<CI.LHFL'C"FT1%4QR'C(+DGKUSQTKU*JJPQ+*TJQ*LC !F"C)
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M=Z]]B;?"CX(W*#@\&F+!"BE4A14)W%0H )]:L4 %%%% !1110 4444 %%%%
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MOE0#GU^M/:"%@5:%&4MNP5&,^OUJQ56XN(+6WDN+J9((8QN>21@JJ/4D]*
M6MJJ;%MXPO)VA1CGK5KH*P)/&'A>&UBNI?$6G)!*,I(;A<-^M:BW=HUD+U;F
M(VQ3S!-O&PKUW9Z8]Z +=%8G_"4>&_[/74/[>L?L;/Y8G^T+L+?W<YZU+)K6
MCQWT-C)JEJEW.NZ*$S*'D'8@9YH UJ*** "BBLV;5M+L[^+3[G4;:&[F4M'
M\JJ[@=2 3DT :5%4+&^LM2M5NK"[ANX&) DA<.I(X/(J_0 45B#Q)X>:-Y%U
MJQ,:3"W9A<+A9#_ >>OM6W0 45GZAJFGZ7&DVI7T-G&[B-6F<*&8] ,]Z6WU
M*PNKN>SMKV">XM\>;%'(&://3<!TH OT45E2:UI$%Y/9S:I:QW%O'YTL;2J&
MC3^\P[#WH U:*J65[9ZE9QWEA=175M(,I+"X96'L14SR+'&9)&"HHRS$X %
M$M%8L/B3P]<&U%OKEC(;MBMN%G4^<1U"\\_A6U0 45G7FJ:;83V]O>WT%M+<
MMLA220*9#Z*#UI;'5=,U)IUT_4+>[-N_ERB&0/L;T..AH T***S$UK1Y)[R"
M/5+5I+/_ (^5$JYA_P![T_&@#3HJ-661%9&#*PR".012DJJEF. .23VH ?16
M4NLZ0US;VL6J6KSW*&2&-9E+2J.I49Y'TK5H **ISW-O;E!/-'$97$:;V WL
M>@&>I]JCLM4TW4FG6QU"WNVMW\N40R!S&WH<=#0!H445DW&MZ/8QR27NJVEN
MD<@BD:295".>BG)X)]* -:BHU964,K J1D$="*BFFBM[=YIY%CB0;F=S@*/4
MF@"S15%;RUDGBA2ZB:26/S8T#@ET_O =QR.:O4 %%4Y+JWAN8;>2:..:<D1H
MS ,^!DX'? HM[FWN5=K>=)E1BC%&# ,.H..] %RBBLY=2T]@I6^@(:4PJ1(.
M9!U4>_M0!HT45G7VJZ;I?D_VA?V]GY[B.+SY F]CV&>IH T:*SK35M-OKFYM
M;/4+>XGM6VS1QR!FB/HP'2M&@ HK*;7-%ANY[.75+5+FWC\V6)IE#1I_>(SP
M*LV=[9ZC9QWEC=175M(,I+"X=6'L10!<HJK<W-O9VTEU=3QP01C<\DC!54>I
M)JC#X@T.[GM[>UUBSFFN4\V&-)U+2+_>49Y% &Q11566YM[=HDFG2-I6V1AV
M +MZ#U- %JBLZQU33=1DN([&_M[I[9_+F6&0.8V]&QT-:- !167=:QI=C%<2
M7FI6MNEOCSFDE51'GINR>,U:@GAN($GMY%DBD4,KH<JP/0@]Z +5%(3@9/ J
MC8ZCI^I0--I][!=QHYC9X9 X##J,CO0!?HHJAJ&I:?I5K]JU.\@LX<A?,GD"
M+D]LF@"_14,<B21K)&P=&&593D$>M34 %%4S=6ZW2VK7""X=2RQ%AN('4XZX
MJY0 44F<#)X%4K+4+'48&FL+R&[B5BA>%PX##J,CO0!>HHJA=:A8V A%]>0V
MWGN(XO-<+O8]%&>IH OT444 %%4(]0L9K^:PBO(I+J!0TD"N"Z ]"1U%7Z "
MBJ\DD=O$\LSK'&@+,S'  ]2:99WEIJ%I'>6-S'<V\@RDL3!E;Z$4 6Z**H3:
ME8V]Y;V=Q>0Q7-SD0Q/( TF.NT=Z +]%%% !15"UU&PO)KB&SO(9Y+9MDR1N
M&,;>C =#5^@ HHHH **** "BBB@ HHHH *\@\>_#W7?$7BV[U+36@2UOK--.
MNM\F&>#+,X ]=VW'U->OT4 ?/]S\/_B-JGAFST/4Y8VCT^&..-A?'$K*V=RX
M&5POR_A5Y?!/Q(M[G5;FVO(U-\J(B_:L-$5SM<MCYL [<'US7N5% 'B&I>#?
MB=]EM+?2_$-TL2RQS3 WV7+X.X[F'W0<';^E='K'@/6IKG5-277)]5:YEMIU
MTV\<"W;RN60X7@'M^N:N>(OB WAO7S8W&E[+**-99+F639Y@/7R\C#$=P2#5
M2;XBWUF+!;[PU+"^KD+I*).K&=ST1_[AQ\W<8% '/ZIX3\67FMW&H0>$=/MK
M+4HUBN[:VNT678K9(+$;<MT)7M6]JG@G4+RYO]1AO)7MKG2ULTT"68);(1_#
MN49 QT([^U:VH>+KO0?"5_K&O:0+.YMF$<< N%*7+M@($<XP"3CGI5*/XI>'
MV^QR7;&&WN[-+I)(\RY<L5:/"@YVD')Z<4 <UI?@OQ3I^K_VW-H-MJ,7E-;1
MZ;>7,9DB! 'F&15VMTQTW8[U<\/^"->T-&TVXT?2M72ZN([DW\\I'V0#_ED%
MQN(3HF"/?%=-)\3/!<*WSR:P%2R7=(YC8*PX^X<8;J.GK73Z3JUAKFDVVJZ7
M<"XL[E-\4B]&% &A1110 5Y%XL^'^O:OXYO-4T^9!!>P1H9991MA"!@4\O&2
M6R,,",5Z[7%:UXXAT/Q?#H^H6HM=/,'G2:C<$I&&YPBG&">.Y% $G@G1M0TF
MSOI-0LX;%[J976T@<.L05%3J !D[<_C737MNUUI]S;QR>6\L;('_ +I(QFL+
MP;XHB\7Z$^K06CVL8N)(1&[!F(5L!CCID<X]ZZ1VV1LY!(4$X'6@#PO3_AOX
MHTVP5&L;:Z2-'M5MY[E6/S(5,^_;T!.0IY'/->UZ;;-9Z7:6DDF]X84C9_[Q
M"@9_2O/+?XBZE=:)>7\/AW;+:2MYT$\_E-%%_"6#+G<^,*!G)[UZ):S_ &FS
M@N?*>+S8U?RW&&7(S@^XH Y#Q]HM]KUKIZZ;I_VFXMYC)'+]L-N;9RN%DQCY
MP,]*R/ _A/Q%H?C/5-3UB.W*7*$/.D@(E;(.Y% !0'!)W$\]*Z3QIXUT_P &
M:?%<7*_:;JXD"0VRN%9QD;FYZ*H.2:J>&/'$7B?Q!J6FV]JL=M:,RQRF3YY-
MK;2=I'3/0@F@#N:\>\6> ==US6M9ETZU%E#=@/-*+\D7X7!6/:1^Z/'7D5[#
M7 :A\3M!T_Q/?:-,P,5A:M/-="1=OF @>2HSDOR/SH UO!NFZAI/A:"RU)42
M<.[;%8,44L2%9@ &8#J<<UIZW:R7NA7UG%")WFA>,1-(8P^1C&X<K]:J^%M>
M7Q-X6L-=6V-K]K0L86<,8R"1@D<9XK4O9;B"RFFM;8W4Z(2D(8+O/89/2@#R
M2/P3XF73+"QCT.UBCCNDF@,MX)7L(U*GRF8KF1203\I&.*]GKRU/BLPFTFVN
M-#VSWEY)9RA+@%59" =AQ\W7OCH:]2H \_\ &GAW5=8UW2[S3+%6GME*I>F\
M,?V?)&X&/&'# $5+X(T>^L+W4]0U7P_#I%S<%8T2WF1XO*4G: %[\Y)/))JY
MXK\47'AJXL7?2O/T^:01S7'G!60D\!5[GOU%0>"O&R^,HKV:.R%K%"P\K]YE
MV0YP64@8/'N/>@#MJ\E/@74+S_A*;>;2H;:RU&*0B&2\,ZW-P7W+-R/W8 XQ
M_A7K5>:ZC\2DT*YUF'6M+^RR6,:RV\27"L]SN)")CC#'&>^!UH [S389+?2;
M.VFQYD4*(V.1D* :R/%VCZIKWA:[TO2=4&F7%P IF:/>"G\2XR,9'&0:TM(O
MEU30['4HP$%U DVT-NV[E!QGOC-1ZU=WEAI%Q=:?8B\N47*PF01@^Y;L!0!Y
M/I'PY\46>K^%Q*UM!#IXC:ZFMY $(C9MJ*A!8<,!D-@]Z]OKSC3/B=INI:GX
M?TF.WS>ZLKM*HE4BVVYQGN=V#@=<5Z/0!YIXX\%^)/$?B;1-5TW6+:.TT^97
M^R3PD^6>=TBL&&6QQ@BG?#?PGK'A>*\@U)56$A(X\RB9Y"N[+[@!A3D$*<D'
M-;?B3Q-=>'M5TR'^R?M-G>3+ TXF"LKL< *IZ^IY%2^'?$E]JVJ:EI^H:0;"
M:SV-E91*I#9PI(Z.,<CW% &_=)-):2QVTPAF9"$D*[MC8X..]>%M\*_&-O'<
M--?0ZI*=0-TKQ-]G:5FB*-*^[<#@G[O<=*]Y=F6-F5=Y )"CO[5YQ_PL>^0W
M=G-X=QJ5K,PD@6Y!58U0R,=V/O!1TQU[T =YI\,UOIEK;W#(TL<2HYC7:I8#
M!P.PKE_B)X9UCQ9X1FT?1]3BLGDSYB31EUN%QPA(((&<<UUEC>0ZAIUM?6^3
M%<1K*F>N",BLCQ1K%]H>A3:E9Z<M\T/S2*\OEJB#DL3@_E0!QGAGP+XJTGQ]
MI_B#5M6L[R%---I*J0E&BP$VQK\Q&T$$YQ7JU<%HWCI=6UJSA&F/!97I,4,[
M2 MYPC$C(5';!Z^M=[0!Y3XJ\#^+M4^(ECXCTSQ%;V\$*20Q^9;;GLU:,J2G
MS88DGTS6]\._"^I^$_#-QI.J7%O,_P!LEEC:W4J"C8.3DDY)R3S2^(/%E]H&
MLPPMH+W-C(=OG),HD9MI8E4[JN.2<8S5CP7XH'C+PZNL+9_9?WACV"3>#C!R
M#QZ^G44 ;>L6M]?:+=6>FWPL+N:,I'<F/?Y1/?&1FO,O#_PVUC2]$T:VO_L5
MU>:9K;7L<T8*8A;[QY)RQ/)KU6\FEM[*6:&W:YE1"RPH0"Y]!FO/O^%D7BW5
MK:WWAXVVZ[-M<W7F&2WB QR)%7!.3CM@T >FUPOC[0]0U[0DT_3=*ANI),J9
MGF6-K?IAAN4Y4XP0,''2NZZBN9\4:]?^']-%[9Z6+Y$!>4M,(PBCL,]6/0#N
M: ,#P[H.MV?C:[U:\TNTL(#:?9F,$H99FW!MZ*%!7/.=V3G%>BURF@^*&UK7
MM3TM]+N; V,<,@:XP#*) 3D =,8QS75T >0>,/!.N>)]6U2.+0H+*W4;[2ZA
MN41KASC>9.-P) VCJ!UKM?!NFZAI/A6WL=25(YU9V\M6#%%+9"LP #,!U..:
MBN_%%]_PD>HZ!::.WGVME]KCGN91'%-\P! (R1C/6K?A/6KKQ%X;M]7N[ 6,
MDV[$2R;P5#$!@<#@XS0!+XFANKCP[=QV&DV^JW>T&*VN6"QNP/&2>..M<%I_
M@W6H]3\/21Z#;68M;H7EU<O<HS,Q)WJ55?<E-IP,\UZ3JU\VF:1=ZA':RWC6
M\;2""'&]\#H,UR5OXXOK@^'[B/P^ZV.K>4ID-PN]&?/"H/O!?XCQB@#T"N0\
M6>&WUS4-!OK:*/[3I]X)#,QPT<94AMOJ>177US&M>)#HNL:+8?V;/<1ZG<BW
M-PI 2 D9&[N2?2@#F_AKX3UCPK'>V^H;!#PD;&42O*0S$R;@ 54Y^Z<X.:]+
MKG?#OB!M>;4D?39K!["Z:V*3$%GP =W'0'-=%0!YAJWA/5+6^\17^AZ#97KZ
ME+!)$DLBC:X!#RD,,;@#P#79^&].32?#>GZ;':M:K!"%\EG$A0]P6'!_"L+Q
M!XZAT#Q98Z-<6>8K@QJTS2;3EVVKL7'SX/7TKN: *-_%--IMU#;[#-)$RH)/
MNY(P,^U<+\,_#.L^%]/OK?5+:.W$TB-&HE61R0N&Y4 ;?[HQD#J:[V^NXK#3
MKF^FSY5O&TK8ZX R:Y7P3XN/C#39[Y;+[(%9=J"7<VUAD;@0"#C\/0T =K7&
M^.+'5+_1(H=)T2VU.Y,NTF>15,"$89UW#!;' ^M=E7,^+-<O/#NB2:I9Z:MZ
ML/S3;YO+"(.IS@Y/H* -/1[./3]#LK&*%H$@A6,1L^\I@=">]:=4;&Z6^TZV
MO54HL\:R!3R5R,XXJ]0!RDWAUC\2K+Q+!;Q*JV4MM/+GYV)92HQZ<&NKKD[K
MQ%J%IXQL]';16-E=.8DN1*"Y(7<6V==@Z$^IKK* ,[5K.34-%O;*&7R9)X7C
M63^Z2,9KE/ ?AW4]#@O9-1M8;-IE@B6W@DWK^Z389,@#E^O\Z[EFVH6"EB!G
M ZFN>\*^(CXDTNXO6T^73WANI+8PS$%P4.,G'K0!TE>=^//#&K:Y?6L^GPP7
M*FWDM&6:3;]G+D8F7CDKCH.:]$KF/$GB)O#[Z:?[-FNUO;M+4R1D!8=QQN;/
M]* .AA3RH(XV;<44*6]<"IJ** /-M%\(ZQ8^/9=1F2%;2*>YG6Z63,ER)@,1
MLO4!,=SZ8KTFN9L?$37GC#4O#C:;-;_8H$F6XD(VS!B1\H]!CO734 8'BK2[
MC6O"U_IEHP2>9,(6. 2"#@^QQBJ7@K2[[2=)N?M]O'9RW=P]P+2%]Z6X.!M!
M'!Z9X]:Z"\N&M+">Y6![AHD+B*/[SX'0>]9WAG7/^$C\,V>M?9'M/M*EO(=@
M6CP2,$COQ0!NUYSXH\*ZOJWBN*]M8X7MIUMT:X>3#V7E2^864=]PXXQ[UZ-7
M&:YXRCTGQ!'IW]GM/!&L3WDX<#R5E?8A _BYZ^U '9TQUW1LH."01GTI]-9@
MB%FZ 9- 'G_@KPOJVBZQ<7-_###'%"ULKQ2;C=YE+^:P['!Q@\UZ%7'>&?%W
M_"0:G+:M8M:HT9N+5R^[SH@Y0DC^$[AT]*[&@ HHHH **** "BBB@ HHHH *
M*** "BBB@#E-6\#Z+K6K/?WS7;K+M\^T%PPM[C;]W>G0XJDOP[\-['CECO)U
M">7;^==.WV-<YQ#S\G('(YX]*[BB@#DX?!.AK;0P7D<^HB*X^ULU[,9C++C
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MO1_"NDZ'?7-YI\,HDN,C$DA<1*3N*(#]U<DG [UTE%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_s3img17.jpg
<TEXT>
begin 644 cvm_s3img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &< C$# 2(  A$! Q$!_\0
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MN0-S' R3@?K7SGX-\+V=GXV^%G@V2VB\_P (Z+-K6H2;1E;FX^1(B>H.]Y&
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MZ8K/TWXB>/K3PMXB^)U[KD<_A#1+V^CM]/%DD;7ZJ1# JL =D:N 2V2Q);L
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MJ "BBB@ HHHH **** "N8\3>"_"_C2VAM?%.BP:M!"Q>.*?<44^N <$UT]%
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MQ;[2HC '  !('IFNRHH Y*'P'X0@U#2K^W\/6<=SHT(M;&01_P#'O$#D(O;
M/(]#@]14GB?P5X7\9Q00^*-&AU6*V):..?=M4G'. 0">.O:NIHH S%TVQ72!
MI/V97L1%]G\F3YU,>,;3G.1CCFN;C^&W@>'PW<^&8_#=K_8]UM$MHVYD8*<J
M.3P >0!QFNWHH XVS^'?@_3M;CUJR\.VD.H1JJ"X"DL0OW=V3\Q'4$Y(/.:T
M+KPGX=OO%$'BB[T:VGU>"#[-'=NN76+);9Z8RS'ZFNBHH YC0/!OACPN\LGA
M_0[;3GE&UFB7G;G.T9^ZN23M&!GM5?Q-\/?!OC2ZM[CQ9X=M-8DM5*0FY4MY
M8)R<#/?C\JZ^B@##M_#^CVFD:?I-OIL,5AIQC-K;JOR0F/[F!_LX!'N >M2:
MMI-GK5D+&^C>6V+AI(E<JLH'\#X^\I[J>#WK8HH XWQ!\/\ PSXEUBVU75[%
MKB:!$B,8E98IT1_,19$!PX5P& /<5I>(_"^@^+M*&E^(M-CU&R#!_(E+;"1Z
M@$9^AKH** ,C2]%TS1=$AT32[-;;3X4,<<"DE44_PC)SCFJD/A/PW#X2_P"$
M1BT6T70?+,)L/+S$4/)7!]SFNBHH Y#_ (07PG_PC5UX:/A^T;2;U@US;LI(
MG(8,"Y)RV"!U)Z =*FN? ?A"\765NO#]G*-;CBBU#<G_ !\I$,1JWLHZ5U-%
M &%!HND1^'W\.KIL":286MVM-F4:-@0P([YR<YY.23UJEI?@OPKH^A7&A:7H
M=M;Z9=1F&:V"DJZ$$;#DGY<$X'09..M=510!SOA_PMH?A6S^P^']+AT^W./D
MCR> , 9))P.PZ"J]UX0T.^T#4M#NK=Y[74V,ET6D8R2L2"&+YSD87'H% '2N
MJHH Y_P[X;TKPOICZ?I=NT<<LKW$TDCF22>5SEI'<\LQ[DUEVWP[\%6#VS6O
MAFRB-M>?VA#M0_NY^?W@YX/S-[98GN:[2B@#GM'\*^'?#^HW]]HNCV]E<ZE,
MUQ=R1+AII&.68^Y)R:HWOPY\#ZC<ZM<7WANSN)=8V_;F=2?M&,8W<^P_*NOH
MH YQ?!_AE?$%SKZZ%:'4[J$6TUP4RTD87:%.>"-O'TXJ/PWX1\-^$[5[7P[H
M\&FPO@%(LX &< 9)P.2<#CDUT]% '*>(O ?A/Q==6MUXDT.'4IK0Y@:5F_='
M.<K@C!]^M3ZWX/\ #?B2*QBUW2(+]=/8M:F8$F(E=IP<YY'!]:Z2B@#DM-\!
M>#]%&E+I7AVRLUTAY9+$11[1;O(")&7W8$@GTKS#QA\'=<\3>+]7UK[59QZA
M<W"-I^OP7T]K>:9 %4>3Y,:%9@"&(W.N2W->^44 <K?>!_"^J:Q::WJNBVUY
MJUK&L*WCKB1D!SM;'WESSM.14]CX5\.Z7KU_KUAI$%OJ6HMNNKE!\TIX&3[\
M#IZ"NCHH Y)/ ?A&/Q=_PERZ'$-=R3]NWN9,'DC.?N\GY>GM4_B#PKX?\4);
M)X@TF&_2U<R0&3(:,E2K8(((RI((Z$=:Z:B@#R'6OAO?:_\ %72M2U32]$;P
M9I.G2V%I91W$J3(TFTF0(L84<*$"ANF3GG;7<7G@OPGJ%CI-C>^'[">UT>19
MK"!H1LMG48!5>@Q7344 </-\+_A_-!-#)X4L=DUY_:#X4J?M'/[P$'(;D]*+
MKX6_#V]O)+R[\(Z9-/))'*Y:'AGC&$8CID#C.*[BB@#B[OX;^!;]M6:\\+V4
M_P#;)5K[>F1<$$$$\]>!T]*?-\//!=U=V5W<>&K.6:RC6&%F3.$5MRAAT?#?
M-\V>>>M=C10!SEYX+\+ZC?:G?7VAVMQ<ZK:"QO)'7)G@'_+-O]GVJUI>A:/H
MNB1Z+INGPVNGQIY:VZ+\NW&,<]>.*V:* .(TWX8_#_1[V.\TSPII]M/% ]M'
M(L?*1/G<BYZ Y/3U-;&A>&/#_AG1O['T'28=.L#G]S""!S^O^%;]% ')^'?
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M39WD%K?6<MJ\D0D?<0?+)!(7@\_=/(R.GK6W$5)LIEMVMVER6C;[R_*3@^]
M&I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGK6N/",[:D3-;V36AU3^T6;;\T@*,"A&.<%N*IV_@O7+/4;22[\727D7FC=
M+58]ZCD_,&XKT4D*"6( '<U0CE]#T_4M+TPZ3)#;O#! 1#*7)#,68[".R@;:
MP[7PGJEKI6J(=+T1VOYHV.G'?]E0*,;NF=Q.#T[5W!NFE)6SC\T_\]#P@_'O
M^%<UK?AKQ-JUV9(O%_V*W_AMTLU8#\2<F@"HWA&\_P"$<L-+6\B,UE"2L^WY
MC)NRJ@G)"#G'X'M4NH2:UH?AZQ_TR-KU9F^>13*%4@X7)(+8&!FJ'_"OO$O_
M $/3_P#@"O\ \536^'?B)QA_&Y8?[5@A_P#9JD9%8^.-1T^_3_A(/)FTQ@ U
MS!$4:V;U9<G*'U'3Z5Z)%+'/"DT++)&X#*ZG(8'N#7GG_"M]=Q@^,E(]#IT?
M^-6?!>EZGX9\1:AX=GUDZE8_98[R%# (A;LSNK*N"?E.T''8YIJX'HE%%%,0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ,K \6?\BW<?[T7_ *-6M^N?\6?\BS<?[T7_
M *-6JC\2(E\+]&6+7_CW6IJSI[Z/3M)-U+#<3*,+MMXS(_/H!7'^'_$>M:CX
MM32]0-W#9PY:WE^R%#? @\R$_<V\ @=3@Y[5TMG&EH=TO_(=M/\ KC-_-*V?
MXJQT_P"0]:?]<)?YI6Q_%7-/=&N'^%^O^0^BBBI.H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N;\#_ /(F6G_72?\ ]'/725S/@<_\4;:?]=)__1ST
MF!TN:,TW=1NJ+CL.S1FF[J-U%PL.S2TS=1NHN%C.>29M2D\NW9_+4(K-PHSR
M3G\JG%FTA#7DGG'^X.$'X=_QJWNI:=P$ "@!0 !V%.I**+B%HI**+@+7-0?\
ME+OCZ:7 /_(LE=)7.6?/Q'U4^FGVX_\ 'Y*:8'244450!1110 4444 %%%%
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M+-#XWN?,TR$2:?($FN%OFDMUS'N001'D'$ASNX7)QUK=[G-'X3TA/^0]:?\
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MX['1[J-U1[J-U $FZC=4>ZC=0!)NHW5'NHW4 2;J-U1[J-U $NZEW5#NHW4
M3;J-U1;J7=0!(#R*UOA_SH%Z?74;G_T.L4-R*V?A[SX:N3ZZA=?^C330CL:*
M**H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\__ ! \
M&B_\8WNJ:M8'Q!>?VBDUKIJZQ]FEGT[[*$:.)#(JJ4FW.<XW=<]J^@*\%U[0
M_$$?Q:N]:\-^'](\4W":BMY+*VH117-FGV/R/LT@8$K'G]X,=0YXSR0#TOX?
MZ;?:3\.-!TW451;NWLT1U202 <<#>.&.,98<$Y(KKZYKP7HMUX=\$:1H=],D
MUS9VZQR-'G8#_=7/.T=![ 5TM !1110 E)2U4-N^V1?M4OS]#D97Z<5+;6RN
M-(M456^SR?N_]*E^3W'S_7BC[.^Z0_:I?GZ#(^7Z<5/-+L%O,LT55^ROY<:_
M:I<H<ELC+?7BE^SR>8\GVB3## 7(PON.*.:78+(LT54^RR>2L?VJ;@YWY&X^
MW2G>1)YQE\^3!&-F1M^O2CFEV"WF6JSM0T^TU*S>UNH1+$W8]0?4'L?>I?LK
M^28_M4W7._(W?3I3O(D\X2_:), 8V9&T^_2FI2["<4^IQTG]H>%Y?](9[S3"
M<+<8RT7L_P#C6G)JJR+%'8H;FXF&41#V]2>P]ZVS9L8'B:YE8.>IP2!Z=.E5
MK'1K33L"RS N<LJ8PY]^*WC6?VEJ<L\/?2,K(AT_26BF%Y?N)[KL<?+'[*/Z
MUMU6^S/MD7[5+\_0Y&5^G%'V:3]U_I4O[OKR/G^O%8RG*3NT;PIQIQY8EJBJ
MOV=]TC?:9?GZ#(POTXIIM9/+C7[5*-AR6R,M]>*GFEV-+%VO(-?OSK?C>]N4
M):UTL&Q@]#)P9F'X[4_X"U>I-"X:23[1)RI 7C"^XXKS;PQ\/]!U+PQ8ZA<7
M&IK+<J99!%?2*NXL23@'US1=O2P[+N:.@Q6MSHFKZ?=72VPNX_*W-U&5(R/S
MJU)X?TGSE:WUA((F%NTT2XVR20L"K^Q(&#Z\>E,_X5CX9_Y^M7_\&$G^-'_"
ML?#/_/UJ_P#X,)/\:JXA%\"Z;J$;QRZD9X?/><1P (L;%< J!P#G#'L3VKH+
MW1YM0TVQAFOO]/LY%FCN1&,%P",E>F"">*R]/\ Z'I=]'>6=[JJRH<@-?2,I
M^H)P:Z/S+JW_ .GF/U'#C^AIW$9&D^&(]-U,:E]L>:9HY1+E0 [R2!V;';IC
M%9UYH6GW&J2LVL1QVDMU]JN+8@;C)LV'#9R 178074-QGRW^8=5/!'X5QVL>
M"-%U37WNKZ:^B>X4;?L]T\2[AUX'&3UI@9__  ANDKI<FGQ:]'#&RK$6C&&D
MB ("N<\]<\8&1TJX- L0/)_MY#!(UM)(I49:2$* 0>P(0<4G_"L?#/\ S]:O
M_P"#"3_&C_A6/AG_ )^M6_\ !A)_C4W&:VFQV^FZA<O%K$#VES++</$V-PD=
M@1@^@ -95CHKP)K$=YXL2X35 _F,(E1T+<<-G. O ':C_A6'AG_GZU;_ ,&$
MG^-'_"L/#/\ S]:M_P"#"3_&G<9K7EKH]Y86VF#44AL;=-OE1L!NPN$Y]NOU
M K$N;&STOP@^GV^H)=.TXD.W  [<#MTR?<DU+_PK#PS_ ,_6K?\ @PD_QH_X
M5AX9_P"?K5__  82?XTKB.6"MG[IJOX./_%'V/UD_P#1C5V0^&/AK(_TK5__
M  82?XUQOAB&.T\.06L)8QPR31KN;)P)7 R>YI#-[=1NJ+=1NH EW4;JBW4;
MJ )=U&ZHMU&Z@"7=1NJ+=2[J )-U&ZH]U&Z@"3=2[JBW4;J )E;YA6[\._\
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M/_).-&/K&Q_\?:@1UE%%%4(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"G&'_T 4"-VBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ +]%4/[9TO_ )_8_P Z/[9TO_G]C_.@"_14<<B2QK)&P=&&01T-24 %%%%
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M4J66^3!Y)_K7SV:XRAB(15.5[-GT63X.MAIR=2-KI#,T9K6_X0[QQ_T+L/\
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M"TG[7:W0L81-:H(X7"\QJ. !].WI6Q110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_s3img16.jpg
<TEXT>
begin 644 cvm_s3img16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &6 =<# 2(  A$! Q$!_\0
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MS$(4()#G<!E3@X89!P<$U3\+^.K/Q5XHUS3M- DL=.AM9$F,<D;NTOF[@RN
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M37-4DO;>.52C>0$2&-BIY!98@^#V85W5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !115:2;:WEQKOD/\([>Y]* )9)$B3<[8'ZFH-DDQW2,
MT:=D4X/XD?RI\</S>9*V^3U[+]*L4 5_LL?]Z7_OXW^-'V6/^]+_ -_&_P :
ML44 5_LL?]Z7_OXW^-'V6/\ O2_]_&_QJQ10!7^RQ_WI?^_C?XT?98_[TO\
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M/^]+_P!_&_QH^RQ_WI?^_C?XU8HH KK"BD,&D./60D?SJQ110 4444 %%%%
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MD_Z!EY_WPO\ \55G;=?\](O^^#_C1MNO^>D7_?!_QHOY!9]RM_:,G_0,O/\
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MM6?K'_(*E_WD_P#0Q6@.E9^L?\@J7_>3_P!#%-;HGH:5%%%(H**** "BBB@
MHHHH **X'XN:M<:#\&_%6H622/=_8'@MUC4EO-E_=I@#_:<5P/P;^&^O>%O%
M,^N:AH:>&;5-'M])%B+_ .UO?3(VY[N0@E5)Q@ <XSTH ]RN+B"UMY+BZF2"
M*,;GDD8*JCU)/ K'UWQ)H?AGP_+KVO:I#8Z9$%+7$ARO)PN,9+$DC &2>U>=
M>-/AKXBU3QH_BE9K/QCIPVF/PQKDKQ6T!4#+0E,QECC_ ):QM]16U\5_#.M>
M*O!.F1Z#9PS:GI>J6>JI82S"-9_)?<8=_09&<$\<4 =7X=\5>'_&&D#5O#NI
M1ZC9>8T1= RE'7[RLK ,K#T(!K+T[XE>!=6\63^%]/\ $UK<ZS 9$:W7<,M'
M_K%5R-K%>X4DCO7)> M'\=>&IM7U>\\*P?:?%7B5KV[LEU"/_B56C(%\PL!B
M5\H,JO7/7BN(T'X3^.H]:T#P[J&FV]GHWAV_U6]77$NU=KU;I7$:K$/G5AYG
MS;N/EXS0!ZQIGQ:^'.M'5$TOQ5:W9TNWDNKK8K_+"F=\BY7]XHP<E-PK0\)?
M$3P?XZ:9?"^J/?>3&LKDVDT*[6Z$&1%#9]LUXOX1^&?CR&32;?Q'X4LTLO#/
MAJ\T-(H]27&MM,<8#*,Q(5'5N03TKJ_A+X-\5>&?$&M7%SI5UX8\,2VT-O8Z
M!<:P=1,4JYW2JV6$:D84*#V[8% 'M]%%% &;J7WK'_KZ3^1K1K.U+[UC_P!?
M2?R-:-#V1*%HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY[6=$?4I[&[M;][.^L'9X)@@D7YEVLK*>H(/J#[UT-% ''+X.^SPVTUEJDL6
MJ0W$UT;QHU82/+_K 4X&T\8 QC:.>N=*QT633/#CZ79WLJS,)&-VR@N99&+-
M)C@9W,3CI6_10!QTG@NW-Y;M;7LEO91K;+):A WF_9W+Q?,>5Y//K[5V-%%
M!113'D2-"SMM4=Z 'U5,KRDI!P.\AZ#Z>M(%DN/]9E(O[G=OKZ?2K( 4 *,
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M2_\ CQ;_ *[S?^C6HNW'45DF5M2F<M8_Z-*/]*3^[Z'WK0\^3_GUF_\ '?\
M&JNI_>L?^OI/Y&M+M1T0+=D'GR?\^LW_ ([_ (T>?)_SZS?^._XU/1040>?)
M_P ^LW_CO^-'GR?\^LW_ ([_ (U/10!!Y\G_ #ZS?^._XT>?)_SZS?\ CO\
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M'VFW_P"?B/\ [Z%!1+147VFW_P"?B/\ [Z%'VFW_ .?B/_OH4 2T5%]IM_\
MGXC_ .^A1]IM_P#GXC_[Z% $M%1?:;?_ )^(_P#OH4?:;?\ Y^(_^^A0!+14
M7VFW_P"?B/\ [Z%'VFW_ .?B/_OH4 2T5"L\+$*LR,3V#"IJ "BBB@ HHHH
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MUU8?^'$G$_QI!7U%^S__ ,DYN/\ K^?_ - 2OES-?4?[/_\ R3FX_P"OY_\
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M<EV9QGBW_D*P_P#7'_V8US];_BW_ )"D/_7'^IKG2:[<-_"B<V)_BR%KZ>^
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MRC_24_A'H?>M#[0W_/O+_P!\C_&GT0+=EBBH/M#?\^\O_?(_QH^T-_S[R_\
M?(_QH*)Z*@^T-_S[R_\ ?(_QH^T-_P ^\O\ WR/\: )Z*@^T-_S[R_\ ?(_Q
MH^T-_P ^\O\ WR/\: )Z*@^T-_S[R_\ ?(_QH^T-_P ^\O\ WR/\: )Z*@^T
M-_S[R_\ ?(_QH^T-_P ^\O\ WR/\: )Z*@6<LX7R9%SW(XJ>@ HHHH ****
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M\Q5E[Q_2%)DFZC=4>:,UC8VN2;J-U1YHS18+DFZC=4>:,T6"YR'BS_D)P_\
M7(?S-<]FM_Q6?^)G#_UR_J:YZOH<-_"B?.8G^+(7-?5'[/?_ "3>Y_Z_Y/\
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M5;$T_7*0^G1F_P !^M "M*SL8[?!QPSGHO\ B:ECB6,''+'JQZFGJJJH55
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M;E/^[Q]/U/RW-_\ >9^J_(FW4;JAW4;J]4\@G#<4NZH U+NH FW4;JAW4;J
M)U;YA7EUXW^G3_\ 71OYUZ6K?,*\PO&_TZ?_ *Z-_.@"(M5C3&_XG-E_UW3_
M -"%4BU6M+/_ !.K+_KNG_H0H _0*BBB@ HHHH **** "BBB@ HHHH ****
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MKAJ7=0!/NHW5!NHW4 6%;YA7F-XW^FS_ /71OYUZ.K?,*\UNV_TV?_KHW\Z
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M0,5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_s3img15.jpg
<TEXT>
begin 644 cvm_s3img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &\ >P# 2(  A$! Q$!_\0
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M$6=+0B0A )5VN&7HV1ZU4?X=^%9/&8\6-IY%^-+;1_+5ML/V8L6*>6..I/-
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ME:62:5OO2.[$EF.!R?2NGH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ6G27-M&8XY\62R!PA)VG$@!&3RIKI_'$*ZIXJ\&>&[K_D'7=[+=W,1^[/\
M9XC)'&WJ/,*N1W\NMZP\)^'=+_LY=/T>W@&G-(]KL7F)I!B1L]RP)R3DFCQ-
MX>.NQZ;/:WGV#4-,O$O+2Y\O>%8 JZ,N1E71G0C(^]GJ!0!P>N>-/& A\0:]
MI5Y86>FZ)K$6D_89[-I9;C,D*O(9/,79GS3M 4\ $YSQ=_X2SQ!YOC'6]1US
M3],T+P[>SVB*-/>>1P((V5F(D&2'D&%49;ID9JQX@^%MOXD\9'6+RXTZ.S>>
MWGDCBT\BYD,15@#-YFWDH/F\O>%^4,!79MX?T5['4[&32[=[757>2]B=-RW#
M,H5BP/7*J!^% 'EEMXZ\=1V7BF&[TUIKS0K6TU6,7-@MM+=6S/)YT?EK-)AM
MD3[22#DX*^NM-J2_$CP5XNO89H3X>B!71;R-?G,L*;S=*V?X9L!<8_U1]:ZF
MP\%Z'HMCJ*^&;"#2+^]MOLYN]AE;@-L+[CE]I<G!/MFJ;>!;>W^&-M\/]+O#
MI^GQVR64TJ19>2#I*!R K.-PW<XW$XH W_#.HS:OX0T75KA0D][8P7$B@8PS
MQAB/S-;=5H8(K:".W@C$<42A$11@*H& !5F@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **J><\A(MXPZCJ[-@?AP<U)NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 3
M1NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^
M>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P_
M_$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 3
M1NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^
M>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P_
M_$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 3
M1NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^
M>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P_
M_$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 3
M1NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^
M>,/_ '\/_P 31NO/^>,/_?P__$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P_
M_$T 3T5!NO/^>,/_ '\/_P 31NO/^>,/_?P__$T 3T5%'YV#YB*OIM;/]!4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4457DFV$(J[Y#T4?S/H*
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MR3RS'DL?>I0 JA5  '0"G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3GG 8$9QZBN&&M:Q#IVI0V6JS7EJ^IVVGV.I3(A<;V5)2,*%<*Q8 XQGCG%
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MD/\ 2J"?\AZX_P"O>/\ ]">K_I5!/^0]<?\ 7O'_ .A/7*=#+]%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &/K6FKK&BW&EM=7-HEPNUIK
M5@L@&>0"0>O0\=":SD\*Q_V*^DW6K7EQ;_N_(RL,1MBAW*T?EHN"" ><]*ZF
MB@#G])T2/29;NX^TW%Y>7;AY[FXV[WVKM484!0 .@ '?UJK=>$;.XAC5+Z\M
M[A)IIC=1,OF.900X.5(P00.G&U<8Q7544 5+.U@L+"WL;5=D%O&L4:YSA5&
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MP':@!-DTGS2.T2]E4\_B:=]F/_/Q-_WU5BB@"O\ 9C_S\3?]]4?9C_S\3?\
M?56** *_V8_\_$W_ 'U1]F/_ #\3?]]58HH K_9C_P _$W_?5'V8_P#/Q-_W
MU5BB@"O]F/\ S\3?]]4?9C_S\3?]]58HH K_ &8_\_$W_?5'V8_\_$W_ 'U5
MBB@"O]F/_/Q-_P!]4?9C_P _$W_?56** *_V8_\ /Q-_WU1]F/\ S\3?]]58
MHH K_9C_ ,_$W_?5'V8_\_$W_?56** *_P!F/_/Q-_WU1]F/_/Q-_P!]58HH
M K_9C_S\3?\ ?5'V8_\ /Q-_WU5BB@#YR_:$C\O6-#_>._[B3[QS_$*\3S7M
MO[0W_(9T3_KA)_Z$*\0K]!R;_=X?/\SY+'?QY?UT'9HS3:*^A.$=FC--HH Y
M_P 0'_2H?]P_SK%K9U__ (^H?]P_SK&KPZ_\21Z-+X$?4'[+,?F:3XG_ 'CI
M^^M_NG'\+U]&_9S_ ,_$O_?5?.W[*W_(,\4?]=K?_P!!>OI"O@\7_'D?0X;^
M$B#[.?\ GXE_[ZJBEN?[>N!]HF_X]X_XO]IZU?2J,?\ R'[C_KWC_P#0GKE7
M4Z.Q/]F/_/Q-_P!]4?9C_P _$W_?56**!E?[,?\ GXF_[ZH^S'_GXF_[ZJQ1
M0!7^S'_GXF_[ZH^S'_GXF_[ZJQ10!7^S'_GXF_[ZH^S'_GXF_P"^JL44 1QQ
M^7G]X[Y_O'.*DHHH **** "BBB@ HHHH SM2U"STO3)K[4;A+>UC'SNYP!GC
M^9KR[0;CPO<7VD76G^(+S4C<M:B+1QL8VX7)3>P7)6+>QY/89)P*]@?_ %;8
M7<<=/6O)]/U#Q1;ZSI=M?7VH"2Y:UE6P2Q1(A$RGSDR(_E\LCNP.,>N: /6J
M*H7-Q'9VLEU)N$42EFV(7.!Z!02?H!6$OB^QD\''Q5#:W,EJ<[82H61OWGEC
M@D 9/J: .LHKEI?$5Q9Z=]IU#0+RVF>:.W@MS+"SSNYP "KE1[DD5+8^([74
M9[".W@G$MVLKLC 9MQ&VQ]_/]_Y1C.3["@#I***9)(D:;G; _G0 ^J99[@[8
MSM3O)_\ $_XT;)+@[IOEB[1]S_O?X5;Z#C@4 0QQ+$FU1CN3W)]34]%% !11
M10 4444 %%%% !16'9^(=#U#49=-L=<L;J]BW>9;07*/(FT[6RH.1@\'T-6]
M2U33=&L'O]7U"VL+./EY[F58T7ZLQ H T:*Y7Q1XT\/>#]+M;[6[R14O)A!:
MQVT#W$MPY!(5$C!9N 3P.@I;#QAX;U+P0/&MKJL)T'[.]T;QLJJ1KG<6!&01
M@@@C(((H ZFBO-[/XS_#N]\/ZGK4>L30VVF&$7$<]G-%,/-_U.V)E#OO_AV@
MYI'^,7@-?#T.O?VI</!/=O8);)9S-=?:$&7B, 3S RCDY' YH ])HK@9OBIX
M'BM_#5S_ ,)!#(GB>5(M*6-69[DLP7A0,@ D DXP>#7?4 %%%% !1110 444
M4 %%%% 'SG^T1_R&-"_ZX2?^A"O#LU[C^T5_R&M"_P"N$G_H0KPSFOO\G_W>
M'S_,^2QW\>7]=!V:,TWFCFOH3A'9HS3>:.: ,#7O^/J'_</\ZQR:U]?/^DP_
M[A_G6-7AXC^*STJ7P(^I?V5?^09XG_Z[6_\ Z"]?25?-'[+<]O#I7B?SIXXL
MS6^-[ 9^5_6OHS^T+'_G^M_^_B_XU\)B_P"-(^APW\-%OTJC'_R'[C_KWC_]
M">G_ -H6/_/];_\ ?Q?\:I)?6/\ ;D[?;(,?9XQGS%_O/[US+J;]C9HJI_:%
MC_S_ %O_ -_%_P :/[0L?^?ZW_[^+_C0,MT5#%/!,"89DE ZE&!Q^534 %%%
M% !1110 4444 %%%% !1110 4444 -9=R%?48KC='L/&FFP6-C=76CS65N%C
M9E2;S3&..I;&<=S7:5@V_B7P_=7#V]KJEO-(DRP,$;(\QMV%STR=K?D: -.X
ME>&VDFCMY+AD4L(HMNYSZ#<0,_4BN,T&SOH_ 4FEZMX5FN'663?93R0D3(\S
M/P=Y7@$<$CD?C7?44 <%HOAM9O[5AO-+FTO2[B>*6SLA/A[9D',BF-B(R6P<
M*W;/<UF7GAG4H;:.:UTVZ>)YI8VL[:\\N5(@K" ERXW?.S2-\V<R9YVUZA10
M!G:7'>0Z+8PZC*);V."-9Y <[Y H#'\3FKQ16=6*@LO0^E/HH **** "BBB@
M HHHH **** "J%_/-:Z9=7-O;M<S10O(D*\M(P4D*/<GBK]% 'A/PC^%^O:/
M)X<\4>+/LEM?6.G7 6UMXR)FGNY!-.]PYZLI^0*,@<G-=)XH^%ZZSXMB\::?
MJRKK,*JL=MJUN+^Q& .4B8@Q,<?>C8'ZUW?]J%F<1V=S*J.R;T5<$J<'&3Z@
MU-_:4G_0,O/^^5_^*JK,GF1QGQ \(Z[XBN/#.M>'-0L;+7?#]VUU;_;86DMI
M=\31NC!2&'#9!![5SFG_  GURU^%W_"MYM>M9-'N],O8;^9;8B9KN>0R"2/G
M C4NWRGD\5ZM_:4G_0,O/^^5_P#BJ/[2D_Z!=Y_WRO\ \51J',CQ'_A2OBS4
MK#4]0USQ-IA\2.=,^P26MFXM8OL+%HS(K-N8N2=V",=O2I(?@_XQLGM/%-CX
MBTC_ (32+7+O6I#+:2&P8W$(A>(*&W@!5!!SG.<U[7_:4G_0+O?^^5_^*I+:
M^%Q</;M:RP2(H?$J@9!)'&"?2E9CNCQ34/@_XNL_A]X&\)^&M;T5V\-7RZI-
M=:C;2YFN%E,H"A&^6,L[9'7 7D5[A;^=]GC^T;3-M'F% 0N['.,\XS5RBD,*
M*** "BBB@ HHHH **** /G+]HO\ Y#6@_P#7"3_T(5X97N7[1O\ R&M"_P"N
M$G_H0KPO-?H.3_[K#Y_F?)8[_>)?UT'44W-&:]TXAU%-S1F@#!U[_CZA_P!P
M_P ZGT7PW<:D5N+C=!:^O\3_ $_QKLM \*6NO2-J%U+_ ,>[;%B*Y4GKD_X5
MV'_"-X&!> #_ '/_ *]?%9ICG3JRIPW[GT."PRE34Y;'-6MM!96ZV]K&(HU[
M+W]SZU/N;^\:WO\ A&S_ ,_G_CG_ ->C_A&S_P _G_CG_P!>OEVVW=GL)6T1
M@[F_O&DRV<[C6_\ \(V?^?S_ ,<_^O1_PC9_Y_/_ !S_ .O1<9@[F_O&JMQ>
M^5E4;<_Z"K&O02:9<1VRR[]Z;BV,'KC%8-(#Z,_9]=Y- UMW8LQN4Y/^Z:]I
MKQ3]GO\ Y%[6O^OE/_037M= !1110 4444 %%%% !1110 4444 %%%% $;[?
M+8-PN#GZ5Y-I=M;P^(-*LYM<CGTV6.SDMO*L9%<I&TAMA(^=J%B3VRVSMFO6
MGV[&W<KCGZ5YGX?T];DV<]EX=U0:9/<07$5S<WT1(BCSY(V9+!%SD+U]: /3
MZ*** "BBB@ HHHH **** "BF.ZQH7=@JCJ35;$EQ][=%%Z=&;Z^@H 4S,S%8
M8_-QU.< >V>].\VZ_P"?4?\ ?S_ZU3*JHH55"J.@':GT 5O-NO\ GU'_ '\_
M^M1YMU_SZC_OY_\ 6JS10!6\VZ_Y]1_W\_\ K4>;=?\ /J/^_G_UJLT4 9&E
MR7/V27%N#_I,_P#RT_Z:M[5>\VZ_Y]1_W\_^M5?2O^/.7_KYG_\ 1K5H=J'N
MQ+8K^;=?\^H_[^?_ %J/-NO^?4?]_/\ ZU6:*!E;S;K_ )]1_P!_/_K5162Y
M_M^7_1US]F3CS/\ ;;VK7K-7_D89?^O5/_0FIH3+/FW7_/J/^_G_ -:CS;K_
M )]1_P!_/_K59HI#*WFW7_/J/^_G_P!:CS;K_GU'_?S_ .M5FB@"MYMU_P ^
MH_[^?_6H\VZ_Y]1_W\_^M5FB@"MYMU_SZC_OY_\ 6H\VZ_Y]1_W\_P#K59HH
M K>;=?\ /J/^_G_UJ/-NO^?4?]_/_K59HH ^;?VB&D;6M"\R/9_H\G\6?XA7
MAN:]T_:._P"0WH/_ %[R?^A"O":_0,G_ -UC\_S/D\;_ +Q+^N@[-&:;17N'
M&.S1FFT4 >@^ _\ D&WG_78?^@UV"*\CB.-2[GHJC)/X5QW@+_D&7G_78?\
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M .1>UK_KY3_T$U[70!6\VZ_Y]1_W\_\ K4>;=?\ /J/^_G_UJLT4 5O-NO\
MGU'_ '\_^M1YMU_SZC_OY_\ 6JS10!%&TK9\R,)Z?-G-2T44 %%%% !1110
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M'SRQ)/\ %ZDU+_PT)\/?^>FH?^ W_P!E3>%K-_ _N!8BDE\2/7J3_@->1?\
M#0WP_P#^>E__ . W_P!>NC\&_$[PSX[O;JST-[AIK6,22>=%L !./4UG/#U:
M<>:<6D5&M3D[19WM9P_Y&*7_ *]4_P#0VK1K-7_D89?^O5/_ $)JR1JS2HHH
MI#"BBB@ HHHH **** "BBB@#YN_:/_Y#>@?]<)/_ $(5X3FO=?VD/^0WH/\
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M0[O>OC,=_&D?2X7^#$DW4;JCW>]&[WKSSJ)-U&ZH]WO1N]Z .6\4-_Q,(?\
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M_P!_6_QH^QP_WI?^_K?XT <]!\/O!EM()(?#UHK#OLS70V]K;6L8CMH$B0=
MBX%'V.'^]+_W];_&C['#_>E_[^M_C0!8HJO]CA_O2_\ ?UO\:?'&L:[5W$?[
M3$_SH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@""::.W@DGF8)'&I=F/0 #)-8&D^,O"_B"Y>UT76K>\G5=QB1L-
MM]0#@D?2M77?^1;U3_KUE_\ 0#7G_A/2/$&JP^$-6U*VL+*STFQ#6Q@E:2:X
MWPA!NRH"#!R1SSCTH ]1HKQH:AXBTWX9VOB@>(-0O;Z_$5NPFEC2*V1Y0"XR
MN%8#C>^0,Y-:OA.Z\90KJMNT(O-L<4EI#J.K17$FXL0^9(ER%Q@C*GD$9YX
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MYBK;(D@!P",DF,L#GN.U0?VUXRAT76=/MW74M2TS48[62\@M07\AHU<R"'<
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M7/$EOXW>+5KUM)T\WBP6\3Z:9(+F,D!3]H#?*[>A P<#FO2* "BBB@ HHHH
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MGENK=;21EE928U8N ,$8(8DY'-;E% '/Z-X9TC06G;3X9?.G $DT\[S2,!G
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M'_9]NYCED=60H_'RE6 8'D8&,G(Q5G1O$&CZ];23Z1>"X2)MDBE&C=#U^96
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
